UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2021~~2022

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38670

Entasis Therapeutics Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	82-4592913
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

35 Gatehouse Drive

Waltham, MA 02451

(781) 810-0120

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	ETTX	The Nasdaq Global Market
Common Stock, par value $0.001	ETTX	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~April 122, ~~2021~~2022, the registrant had 47,~~637~~851,~~629~~779 shares of common stock, par value $0.001 ~~par value~~ per share, outstanding.

ENTASIS THERAPEUTICS HOLDINGS INC.

QUARTERLY REPORT ON FORM 10-Q

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Balance Sheets	5
	Consolidated Statements of Operations and Comprehensive Loss	6
	Consolidated Statements of Stockholders’ Equity	7
	Consolidated Statements of Cash Flows	98
	Notes to Consolidated Financial Statements	109
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2423
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3533
Item 4.	Controls and Procedures	3533

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	3634
Item 1A.	Risk Factors	3634
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3634
Item 3.	Defaults Upon Senior Securities	3634
Item 4.	Mine Safety Disclosures	3634
Item 5.	Other Information	3634
Item 6.	Exhibits	3735

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information.

Forward-looking statements include, but are not limited to, statements about:

●

the severity and duration of the impact of the COVID-19 pandemic on our business, development programs and access to capital;

●

our plans to develop, obtain regulatory approval and commercialize our product candidates;

●

the timing of execution of planned clinical trials and availability of data from our clinical trials;

● our expectation that the efficacy and safety data from our recently concluded and ongoing Phase 3 ~~registration~~registrational trials, if positive, will be sufficient to support submission of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA;

●

our ability to obtain grants or other government funding to develop our product candidates;

●

our ability to take advantage of benefits offered by current and pending legislation related to the development of products addressing antimicrobial resistance;

●

the timing of and our ability to file, obtain and maintain regulatory filings for our product candidates;

●

the clinical utility of our product candidates and their potential advantages compared to other treatments;

●

our commercialization, marketing and distribution capabilities and strategy;

●

our ability to establish and maintain arrangements for the manufacture of our product candidates;

●

our ability to establish and maintain collaborations and to recognize the potential benefits of such collaborations;

●

our estimates regarding the market opportunities for our product candidates;

●

our intellectual property position and the duration of our patent rights;

● our estimates regarding anticipated operating losses, needs for additional funds and capital requirements and our ability to obtain such financing;

●

political, social and economic instability, natural disasters or public health epidemics in countries where we or our collaborators do business;

● the substantial influence and control that Innoviva, Inc. and its affiliates, or Innoviva, may exert on actions requiring stockholder approval; and

● our estimated needs for, and ability to raise additional financing, and our ability to continue as a going concern.

Table of Contents

●

our estimated needs for, and ability to raise additional financing, and our ability to continue as a going concern.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this document, including, among other things, those set forth in Part I, Item 1A, “Risk Factors,” in our most recent Annual Report on Form 10-K and those set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to “Entasis,” “the Company,” “we,” “us,” “our” and similar references refer to Entasis Therapeutics Holdings Inc. and its wholly owned subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

ENTASIS THERAPEUTICS HOLDINGS INC.

CONSOLIDATED BALANCE SHEETS

UNAUDITED

(in thousands, except share and per share data)


	~~September~~March 3031,		December 31,
	~~2021~~2022		~~2020~~2021
Assets
Current assets:
Cash and cash equivalents	$	4433,~~124~~547	$	5332,~~247~~307
Grants receivable		21,~~967~~146		1,~~890~~258
Prepaid expenses		24,~~143~~490		45,~~160~~754
Other current assets		~~512~~697		~~835~~496
Total current assets		4939,~~746~~880		6039,~~132~~815
Property and equipment, net		~~213~~183		~~222~~198
Operating lease right-of-use assets		~~744~~3,724		~~1,141~~604
Other assets		63303		63303
Total assets	$	5044,~~766~~090	$	6140,~~558~~920
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,~~130~~781	$	~~660~~1,183
Accrued expenses and other current liabilities		87,~~218~~353		78,~~905~~525
Total current liabilities		9,348		8,565
Convertible note - related party		15,010		—
Operating lease liabilities, net of current portion		183		704
Total current liabilities		24,144		9,708
Total liabilities		9,531		9,269
Operating lease liabilities, net of current portion		3,299		—
Commitments (Notes 4 and 10)
Total liabilities		27,443		9,708
Commitments (Notes 4 and 11)
Stockholders’ equity:
Common stock, par value $0.001; 125,000,000 shares authorized and 47,310,254 and 36,637,357 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		48		37
Common stock, par value $0.001 per share; 125,000,000 shares authorized and 47,851,779 shares issued and outstanding as of March 31, 2022 and December 31, 2021		48		48
Additional paid-in capital		~~260~~263,~~764~~457		~~236~~262,~~707~~760
Accumulated deficit		(~~219~~246,~~577~~858)		(~~184~~231,~~455~~596)
Total stockholders’ equity		4116,~~235~~647		5231,~~289~~212
Total liabilities and stockholders’ equity	$	5044,~~766~~090	$	6140,~~558~~920

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

UNAUDITED

(in thousands, except share and per share data)


	Three Months Ended ~~September~~March 3031,				~~Nine Months Ended September 30,~~
	~~2021~~2022		~~2020~~2021		~~2021~~		~~2020~~
Operating expenses:
Research and development	$	910,~~282~~992	$	9,~~387~~370	$	~~28,638~~	$	~~31,249~~
General and administrative		4,~~320~~936		3,~~213~~307		~~10,938~~		~~10,235~~
Total operating expenses		1315,~~602~~928		12,~~600~~677		~~39,576~~		~~41,484~~
Loss from operations		(1315,~~602~~928)		(12,~~600~~677)		~~(39,576)~~		~~(41,484)~~
Other income:
Other income, net:
Grant income		~~1,208~~672		1,~~458~~972		~~4,444~~		~~1,519~~
Interest income		34		94		10		~~170~~
Total other income		1,211		1,467		4,454		1,689
Interest expense		(10)		—
Net loss	$	(12,391)	$	(11,133)	$	(35,122)	$	(39,795)
Total other income, net		666		1,976
Net loss per share —basic and diluted	$	(0.26)	$	(0.37)	$	(0.84)	$	(1.97)
Net loss and comprehensive loss	$	(15,262)	$	(10,701)
Weighted average common stock outstanding—basic and diluted		47,310,254		29,960,219		41,869,412		20,151,570
Net loss per share —basic and diluted	$	(0.32)	$	(0.29)
Weighted average common stock outstanding—basic and diluted		47,851,779		37,078,478


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Other comprehensive loss:
Net loss	$	(12,391)	$	(11,133)	$	(35,122)	$	(39,795)
Net unrealized loss on investments held		—		—		—		—
Comprehensive loss	$	(12,391)	$	(11,133)	$	(35,122)	$	(39,795)

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

UNAUDITED

(in thousands, except share data)



Three Months Ended March 31, 2022				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of December 31, 2021	47,851,779	$	48	$	262,760	$	(231,596)	$	31,212
Stock-based compensation expense	—		—		697		—		697
Net loss	—		—		—		(15,262)		(15,262)
Balances as of March 31, 2022	47,851,779	$	48	$	263,457	$	(246,858)	$	16,647


Three Months Ended March 31, 2021				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of December 31, 2020	36,637,357	$	37	$	236,707	$	(184,455)	$	52,289
Stock-based compensation expense	—		—		869		—		869
Exercise of warrants	672,897		1		1,799		—		1,800
Net loss	—		—		—		(10,701)		(10,701)
Balances as of March 31, 2021	37,310,254	$	38	$	239,375	$	(195,156)	$	44,257


Three Months Ended September 30, 2021				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of June 30, 2021	47,310,254	$	48	$	260,198	$	(207,186)	$	53,060
Stock-based compensation expense	—		—		918		—		918
Payment of financing costs	—		—		(352)		—		(352)
Net loss	—		—		—		(12,391)		(12,391)
Balances as of September 30, 2021	47,310,254	$	48	$	260,764	$	(219,577)	$	41,235



Nine Months Ended September 30, 2021				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of December 31, 2020	36,637,357	$	37	$	236,707	$	(184,455)	$	52,289
Stock-based compensation expense	—		—		2,669		—		2,669
Issuance of common stock in Private Placement, net of issuance costs	10,000,000		10		19,941		—		19,951
Exercise of warrants	672,897		1		1,799		—		1,800
Payment of financing costs	—		—		(352)		—		(352)
Net loss	—		—		—		(35,122)		(35,122)
Balances as of September 30, 2021	47,310,254	$	48	$	260,764	$	(219,577)	$	41,235

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

UNAUDITED

(in thousands, except share data)



Three Months Ended September 30, 2020				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of June 30, 2020	27,291,563	$	27	$	211,881	$	(162,621)	$	49,287
Stock-based compensation expense	—		—		664		—		664
Issuance of common stock in Private Placement, net of issuance costs	8,183,878		8		23,410		—		23,418
Net loss	—		—		—		(11,133)		(11,133)
Balances as of September 30, 2020	35,475,441	$	35	$	235,955	$	(173,754)	$	62,236


Nine Months Ended September 30, 2020				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balances as of December 31, 2019	13,291,563	$	13	$	176,103	$	(133,959)	$	42,157
Stock-based compensation expense	—		—		2,199		—		2,199
Issuance of common stock and warrants in Private Placement, net of issuance costs	22,183,878		22		57,653		—		57,675
Net loss	—		—		—		(39,795)		(39,795)
Balances as of September 30, 2020	35,475,441	$	35	$	235,955	$	(173,754)	$	62,236

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED

(in thousands)


	~~Nine~~Three Months Ended
	~~September~~March 3031,
	~~2021~~2022		~~2020~~2021
Cash flows from operating activities:
Net loss	$	(3515,~~122~~262)	$	(3910,~~795~~701)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		7924		~~109~~28
Stock-based compensation expense		~~2,669~~697		~~2,199~~869
Amortization and accretion of investments		—		(38)
Changes in operating assets and liabilities:
Grants receivable		~~(1,077)~~112		(~~279~~669)
Prepaid expenses		21,~~017~~264		~~993~~1,449
Other assets		~~720~~60		~~460~~(374)
Accounts payable		~~470~~598		(~~698~~226)
Accrued expenses and other liabilities		(~~436~~1,244)		(~~662~~475)
Net cash used in operating activities		(3013,~~680~~751)		(3710,~~711~~099)
Cash flows from investing activities:
Purchases of property and equipment		(709)		—(11)
Proceeds from maturities of short-term investments		—		25,000
Net cash used in investing activities		(9)		(11)
Net cash (used in) provided by investing activities		(70)		25,000
Cash flows from financing activities:
Proceeds from the issuance of common stock in Private Placement, net		19,951		57,867
Proceeds from the issuance of convertible note		15,000		—
Proceeds from the exercise of warrants		~~1,800~~—		—1,800
Payment of financing costs		(124)		—
Net cash provided by financing activities		15,000		1,800
Net cash provided by financing activities		21,627		57,867
Net increase (decrease) in cash and cash equivalents		1,240		(8,310)
Net (decrease) increase in cash and cash equivalents		(9,123)		45,156
Cash and cash equivalents at beginning of the year		32,307		53,247
Cash and cash equivalents at beginning of the year		53,247		16,034
Cash and cash equivalents at end of the period	$	33,547	$	44,937
Cash and cash equivalents at end of the year	$	44,124	$	61,190
Supplemental disclosure of non-cash investing and financing activities:
Financing costs included in accrued expenses and current liabilities	$	228	$	211
Financing costs included in accrued expenses	$	92	$	—
Right-of-use assets obtained in exchange for operating lease liability	$	3,289	$	—

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

1. Organization and Description of Business

Entasis Therapeutics Holdings Inc., or Entasis, or the Company, is an advanced, late clinical -stage biopharmaceutical company focused on the discovery, development and commercialization of targeted antibacterial products that address high unmet medical needs to treat serious infections caused by multidrug-resistant pathogens. The Company has four subsidiaries: Entasis Therapeutics Limited; Entasis Therapeutics Inc.; Entasis Therapeutics Security Corporation; and Entasis Therapeutics (Ireland) Limited.

On ~~April~~May 123, ~~2020~~2021, the Company entered into a securities purchase agreement, or the ~~First~~Third Securities Purchase Agreement, with Innoviva, ~~Inc., or Innoviva,~~ pursuant to which the Company ~~issued~~agreed to issue and ~~sold~~sell to Innoviva, in a private placement, 14up to 10,000,000 newly issued shares of common stock of the Company at $2.5000 per share, and warrants to purchase up to 1410,000,000 shares of common stock with an exercise price per share of $2.5000, collectively, ~~resulting~~the inThird Private Placement, for an aggregate ~~gross~~ purchase price of approximately $3512.05 million~~, collectively, the First Private Placement~~. As a result of the ~~transaction,~~Third ~~Innoviva~~Private ~~acquired control of the Company~~Placement, ~~owning~~Innoviva owned approximately 5159.39% of the Company’s common stock without giving effect to the potential exercise of its warrants. If Innoviva were to have exercised all of its warrants, as of March 31, 2022, Innoviva would have held approximately 74.9% of the Company’s outstanding common stock.

On ~~August~~February 271, ~~2020~~2022, the Company’s ~~entered~~Board ~~into~~of aDirectors ~~securities~~received ~~purchase~~a ~~agreement~~preliminary, ornon-binding ~~the~~proposal ~~Second~~from ~~Securities~~Innoviva, ~~Purchase~~to ~~Agreement,~~acquire ~~with~~all the ~~purchasers~~outstanding ~~named~~equity ~~therein,~~securities orof the ~~Investors,~~Company ~~which~~that ~~included~~are ~~existing~~not ~~stockholder~~currently owned by Innoviva. ~~Pursuant~~for toa ~~the~~per ~~Second~~share ~~Securities~~consideration ~~Purchase~~of ~~Agreement~~$1.80, ~~the~~payable ~~Company issued and sold to the Investors~~ in acash. ~~private~~On ~~placement~~March 15, ~~(i) 8~~2022,~~183,878~~ ~~newly~~Innoviva ~~issued~~revised ~~shares~~its ofnon-binding ~~common~~offer ~~stock~~to ofacquire the Company atto ~~$2.675~~increase the per share, ~~(ii)~~consideration ~~warrants~~ to ~~purchase~~$2.00. anAll ~~aggregate~~other terms of ~~9,345,794~~the ~~shares~~offer ofremain ~~common~~unchanged. The ~~stock~~offer ~~with~~letters andelivered ~~exercise~~by ~~price~~Innoviva ofto ~~$2.675,~~the ~~and~~Company’s ~~(iii)~~Board ~~pre-funded~~of ~~warrants,~~Directors inare ~~lieu~~publicly ofavailable ~~common~~in ~~stock,~~the toSchedule ~~purchase~~13D anamendments ~~aggregate~~dated ofFebruary 1,~~161,916~~ ~~shares~~2022 ofand ~~common~~March ~~stock~~15, ~~with~~2022, anfiled ~~exercise~~by ~~price~~Innoviva ofwith ~~$0.001~~the ~~per~~Securities ~~share~~and Exchange Commission, ~~resulting~~or inSEC. ~~aggregate~~The ~~gross~~Company’s ~~proceeds~~Board of ~~approximately $25.0 million~~Directors, ~~collectively,~~which ~~the~~does ~~Second~~not ~~Private~~include ~~Placement.~~any ~~The~~members ~~closing~~appointed ofby ~~the~~or ~~Second~~affiliated ~~Private~~with ~~Placement~~Innoviva, ~~occurred~~has onretained ~~September~~MTS 1Health Partners, ~~2020~~L.P. Asand aCovington ~~result~~& ~~of the transaction~~Burling, ~~Innoviva~~LLP ~~owned~~to ~~approximately~~assist ~~52.6% of~~ the ~~Company’s~~Board ~~common~~of ~~stock~~Directors ~~without~~in ~~giving~~its ~~effect~~evaluation toof the ~~potential~~proposal ~~exercise~~consistent ofwith its ~~warrants~~fiduciary duties.

On ~~May~~February 317, ~~2021~~2022, the Company entered into a securities purchase agreement, or ~~the~~Fourth ~~Third~~ Securities Purchase Agreement, with ~~a subsidiary of~~ Innoviva, pursuant to which the Company ~~agreed~~issued ~~to issue~~ and ~~sell~~sold to Innoviva, in a private placement upwhich toclosed 10on February 18,~~000~~ 2022,~~000~~ ~~newly~~a ~~issued~~convertible ~~shares~~promissory ofnote ~~common~~having ~~stock~~a ofprincipal ~~the~~amount ~~Company~~of at $215.000 ~~per~~million, ~~share~~or ~~and~~the ~~warrants~~Convertible toNote. ~~purchase~~Refer up to ~~10,000,000~~Note ~~shares~~6 offor ~~common~~additional ~~stock~~information ~~with~~related anto ~~exercise price per share of $2.00, collectively,~~ the ~~Third~~Convertible ~~Private Placement~~Note. ~~The warrants were exercisable immediately and have a five-year term.~~

The Third Private Placement occurred in two tranches. At the closing of the first tranche, or the First Closing, which occurred on May 3, 2021, Innoviva purchased 3,731,025 shares of common stock and warrants to purchase up to 3,731,025 shares of common stock, for an aggregate purchase price of approximately $7.5 million. At the closing of the second tranche, or the Second Closing, which occurred on June 11, 2021, Innoviva purchased the remaining 6,268,975 shares of common stock and warrants to purchase up to 6,268,975 shares of common stock, for an aggregate purchase price of approximately $12.5 million. At the effective time of the Second Closing, Innoviva owned approximately 60.6% of the Company’s common stock without giving effect to the potential exercise of the warrants. If Innoviva were to have exercised of all of its warrants, as of such date Innoviva would have held approximately 75.5% of the Company’s outstanding common stock.

Going Concern

Since its inception, the Company has incurred recurring net losses and negative cash flows from its operations. The Company has financed its operations primarily with proceeds from the sale of redeemable convertible preferred stock, ~~and~~ the sale of its common stock and the aforementioned convertible promissory note. As of ~~September~~March 3031, ~~2021~~2022, the Company had cash and cash equivalents of $4433.15 million.

10The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements — Going Concern, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Based on the Company’s available cash resources, the Company believes its existing cash and cash equivalents will enable it to fund its operating expenses and capital requirements through the third quarter of 2022. Accordingly, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. A failure to raise the additional funding or to effectively implement cost reductions could harm the Company’s business, results of operations and future prospects. The Company expects to seek additional funding to sustain its future operations and while the Company has successfully raised capital

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~The~~in ~~Company~~the ~~follows~~past, the ~~provisions~~ability ofto ~~Financial~~raise ~~Accounting~~capital ~~Standards~~in ~~Board,~~future orperiods ~~FASB,~~is ~~Accounting~~not ~~Standards~~assured. ~~Codification,~~If orthe ~~ASC,~~Company ~~Topic~~is ~~205-40, Presentation~~not ofable ~~Financial~~to ~~Statements — Going~~secure ~~Concern,~~adequate oradditional ~~ASC~~funding ~~205-40~~in future periods, ~~which~~the ~~requires~~Company ~~management~~may tomake ~~assess~~reductions ~~the~~in certain expenditures. This may include suspending or curtailing planned activities. The Company’s ~~ability~~may also have to ~~continue~~delay, asreduce athe ~~going~~scope ~~concern~~of, ~~for~~suspend or eliminate one ~~year~~or ~~after~~more ~~the~~research ~~date~~and ~~the~~development ~~consolidated~~programs ~~financial~~or ~~statements~~its ~~are~~commercialization ~~issued~~efforts.

Based on the Company’s available cash resources, management does not expect that its existing cash and cash equivalents as of September 30, 2021 will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements through the third quarter of 2022 however management believes it will be sufficient to fund its operating expenses and capital expense requirements into the second quarter of 2022. Management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. A failure to raise the additional funding or to effectively implement cost reductions could harm the Company’s business, results of operations and future prospects. The Company expects to seek additional funding to sustain its future operations and while the Company has successfully raised capital in the past, the ability to raise capital in future periods is not assured. If the Company is not able to secure adequate additional funding in future periods, the Company may make reductions in certain expenditures. This may include suspending or curtailing planned activities. The Company may also have to delay, reduce the scope of, suspend or eliminate one or more research and development programs or its commercialization efforts.

The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Risks and Uncertainties

As aof ~~late~~March ~~clinical~~31, ~~stage company~~2022, ~~Entasis~~the isCompany ~~subject~~had to$33.5 amillion ~~number~~in ofcash ~~risks~~and ~~common~~cash toequivalents, ~~other~~and ~~life~~an ~~science~~accumulated ~~companies,~~deficit ~~including,~~of ~~but~~$246.9 ~~not~~million. ~~limited~~Since ~~to,~~its ~~raising~~inception ~~additional~~through ~~capital~~March 31, ~~development~~2022, bythe ~~its~~Company ~~competitors~~has offunded ~~new~~its ~~technological~~operations ~~innovations,~~primarily ~~risk~~with ofproceeds ~~failure~~from inthe ~~preclinical~~sale ~~and~~of ~~clinical~~preferred ~~studies~~stock, ~~safety~~common ~~and~~stock, ~~efficacy~~warrants ofand ~~its~~pre-funded ~~product~~warrants, ~~candidates~~at-the-market inofferings ~~clinical~~and ~~trials,~~ the ~~risk~~issuance of ~~relying~~a onconvertible ~~external~~note. ~~parties~~The ~~such~~Company asalso ~~contract~~has ~~research~~either ~~organizations~~directly ~~and~~received ~~contract~~funding ~~manufacturing~~or ~~organizations,~~financial ~~the~~commitments ~~regulatory~~from, ~~approval~~or ~~process,~~has ~~market~~had ~~acceptance~~its ofprogram ~~the~~activities ~~Company’s~~conducted ~~products~~and ~~once~~funded ~~approved~~by, ~~lack~~United ofStates ~~marketing~~government ~~and~~agencies, ~~sales~~non-profit ~~history,~~entities ~~dependence~~and onthe ~~key~~collaboration ~~personnel~~agreement ~~and~~with ~~protection~~Zai ofLab ~~proprietary~~(Shanghai), ~~technology~~Co., ~~The~~Ltd., ~~Company’s~~or ~~therapeutic~~Zai ~~programs~~Lab. ~~are~~In ~~currently~~the ~~late~~absence ~~clinical~~of ~~stage,~~positive ~~spanning~~cash ~~discovery~~flows ~~through~~from ~~pre-NDA~~operations, ~~submission~~the ~~and~~Company ~~will~~is ~~require~~highly ~~additional~~dependent ~~research~~on ~~and~~its ~~development~~ability ~~efforts,~~to ~~including~~find ~~the~~additional ~~completion~~sources of ~~Phase~~funding 3in ~~registration~~the ~~trials~~form ~~and~~of ~~regulatory approval~~debt, ~~prior~~equity tofinancing, ~~commercialization~~strategic ofcollaborations, ~~any~~or ~~product candidates~~partnerships. ~~These~~If ~~efforts~~the ~~require~~Company ~~significant~~raises ~~amounts~~additional offunds ~~additional~~through ~~capital~~collaborations, ~~adequate~~strategic ~~personnel,~~alliances ~~infrastructure~~or marketing, ~~and~~distribution ~~extensive~~or ~~compliance-reporting~~licensing ~~capabilities.~~arrangements ~~There~~with ~~can~~third beparties, noit ~~assurance~~may ~~that~~be ~~the~~required ~~Company’s~~to ~~research~~relinquish ~~and~~valuable ~~development~~rights ~~activities~~to ~~will~~its betechnologies, ~~successfully~~future ~~completed~~revenue streams, ~~that~~research ~~adequate~~programs ~~protection~~or ~~for~~product ~~the~~candidates ~~Company’s~~or ~~intellectual~~to ~~property~~grant ~~will~~licenses beon ~~obtained,~~terms that ~~products~~may ~~which~~not ~~have~~be ~~successfully~~favorable. ~~completed~~If ~~clinical~~the ~~trials~~Company ~~will~~is ~~obtain~~unable ~~necessary~~to ~~regulatory~~raise ~~approval~~additional orfunds ~~that~~through ~~any~~equity ~~approved~~or ~~products~~debt ~~will~~financings bewhen ~~commercially~~needed, ~~viable.~~it ~~Even~~may ifbe ~~the~~required ~~Company’s~~to ~~product development efforts are successful~~delay, ~~it is uncertain when~~limit, ifreduce ~~ever,~~or ~~the~~terminate ~~Company~~drug ~~will~~development ~~generate~~or ~~revenue~~future ~~from~~commercialization ~~product~~efforts ~~sales.~~or ~~The~~grant ~~Company~~rights ~~may~~to ~~never~~a ~~achieve~~third ~~profitability,~~party ~~and~~to ~~unless~~develop and ~~until~~market itproduct ~~does,~~candidates. itThe ~~will~~Company’s ~~continue~~failure to ~~need to~~ raise ~~additional~~ capital oras ~~obtain~~and ~~financing~~when ~~from~~needed ~~other~~would ~~sources,~~compromise ~~such~~its asability ~~strategic~~to ~~collaborations~~pursue orits ~~partnerships~~business strategy.

11As a late clinical-stage company, Entasis is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations and contract manufacturing organizations, the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through late-stage development and will require additional research and development efforts, including the completion of Phase 3 registrational trials and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.

The COVID-19 pandemic has, and will likely continue to have, a significant impact on the U.S. economy and businesses. The pandemic has taxed healthcare systems both in the U.S. and around the world, resulting in disruption to or temporary suspension of clinical trials. The nature, extent and duration of the COVID-19 pandemic remains uncertain and the time needed for businesses and healthcare systems to recover remains unknown. The full impact of the pandemic on the economy, including the capital markets, also remains unknown. The continuation of prolonged adverse economic conditions (including due to any resurgence of COVID-19 infections) could limit the Company’s access to financial

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

The COVID-19 pandemic has, and will likely continue to have, a significant impact on the U.S. economy and businesses. The pandemic also has taxed healthcare systems both in the U.S. and around the world, resulting in disruption to or temporary suspension of certain clinical trials. The nature, extent and duration of the COVID-19 pandemic remains uncertain. Although vaccines are now being administered around the world, the time needed for businesses and healthcare systems to recover from the disruptions caused, and changes needed by businesses to adopt new working conditions remains unknown. The full impact of the pandemic on the economy, including the capital markets, remains uncertain. The prolonged adverse economic conditions could limit the Company’s access to financial resources from the capital markets and other sources. It is not possible to predict the full impact of the COVID-19 pandemic on the Company’s business and access to capital in the future. Despite these ~~conditions~~challenges, the Company ~~was~~and ~~able~~its tocontract ~~complete~~research ~~enrollment~~organization, ofor ~~patients~~CRO, inpartner were able to keep the ~~SUL-DUR~~ATTACK Phase 3 ~~registration~~registrational trial, orenrolling ~~ATTACK~~throughout ~~trial~~the pandemic and announced positive top-line data in ~~July~~October 2021. ~~The~~Furthermore, ~~zoliflodacin~~the ~~Phase~~Company 3has ~~registration~~observed ~~trial~~an ~~continues~~increase toin ~~enroll~~the ~~patients~~enrollment ~~and~~rate ~~any~~during ~~future~~the ~~impact~~past bythree ~~the~~quarters ~~continued~~in ~~COVID-19~~the ~~pandemic~~zoliflodacin atPhase ~~clinical~~3 registrational trial. ~~sites~~Consequently, ~~cannot~~the beCompany ~~estimated~~has atguided ~~this~~to ~~time~~enrollment completion in 2023.

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, ~~2020~~2021 and the notes thereto, which are included in the Company’s most recent Annual Report on Form 10-K. Since the date of those consolidated financial statements, there have been no material changes to its significant accounting policies.

Basis of Presentation and Consolidation

The accompanying consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The December 31, ~~2020~~2021 consolidated balance sheet was derived from audited consolidated financial statements. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021, filed with the Securities and Exchange Commission, or SEC, on March 233, ~~2021~~2022. The interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.

The accompanying consolidated financial statements include the Company’s accounts and those of the Company’s wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The results for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 are not necessarily indicative of the results to be expected for the year ending December 31, ~~2021~~2022 or any other future year or period.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and the recognition of certain development costs. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.

12Recently Adopted Accounting Pronouncements

Effective January 1, 2022, the Company adopted ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”). ASU 2021-10 requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~Recently~~model ~~Adopted~~by ~~Accounting~~analogy. ~~Pronouncements~~The adoption of ASU 2021-10 did not have a material impact on the Company’s financial statements and disclosures.

~~Effective~~ On January 1, ~~2021~~2022, the Company adopted ~~the~~ASU ~~provisions~~2020-06, ofDebt ~~FASB~~— ~~ASU~~Debt ~~2019-12,~~with ~~Income~~Conversion ~~Taxes~~and Other Options (~~Topic~~Subtopic ~~740~~470-20): ~~Simplifying~~and ~~the~~Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for ~~Income~~Convertible ~~Taxes,~~Instruments ~~which~~and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for ~~income~~certain ~~taxes~~convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity and modifies the guidance on diluted earnings per share calculations as a result of these changes. The adoption of ~~the~~ASU ~~new~~2020-06 ~~guidance~~ did not ~~affect~~have an impact on the Company’s ~~consolidated~~ financial statements.

3. Fair Value of Financial Instruments

The following tables set forth the Company’s assets that were accounted for at fair value on a recurring basis:

~~September~~March 3031, ~~2021~~2022

Fair Value Measurement Using

Level 1

Level 2

Level 3

Total

(in thousands)

Cash equivalents:

Money market funds

3920,~~134~~138

—

3920,~~134~~138

Total

3920,~~134~~138

—

3920,~~134~~138

December 31, ~~2020~~2021

Fair Value Measurement Using

Level 1

Level 2

Level 3

Total

(in thousands)

Cash equivalents:

Money market funds

4928,~~125~~137

—

4928,~~125~~137

Total

4928,~~125~~137

—

4928,~~125~~137

The Company classifies its money market funds as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment.

The carrying amounts of the Company’s cash equivalents, grants receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these amounts.

4. Leases

The Company holds one significant operating lease consisting of 20,062 square feet of office and laboratory space in Waltham, Massachusetts ~~that expires in December 2022~~ pursuant to a May 2015 lease with AstraZeneca, or the AZ lease, as amended ~~in February 2018~~. During the three months ended September 30, 2021 and 2020, the Company recorded lease expense of $0.2 million related to the lease. During the nine months ended September 30, 2021 and 2020, the Company recorded lease expense of $0.5 million related to the lease. See Note 11, Related Party Transactions, to these notes to consolidated financial statements for additional information.

13In February 2022, the Company made the decision to exercise a renewal option for the AZ lease which extended the lease term for an additional three years. The Second Amendment to the AZ lease was signed in April 2022. Accordingly, the Company updated the incremental borrowing rate for the AZ lease to be as of the date the Company confirmed exercise of the renewal option, and recorded a corresponding increase to the right-of-use asset and lease liability of $3.3 million. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and has allocated all of the contract consideration across lease components only.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

In ~~calculating~~During the ~~present~~three ~~value~~months ofended ~~future~~March ~~lease payments~~31, ~~the~~2022 ~~Company~~and ~~utilized~~2021, ~~its incremental borrowing rate based on~~ the ~~remaining lease term at the date of adoption. One lease contains a renewal option that can extend the lease for three years. Because the~~ Company isrecorded ~~not reasonably certain to exercise this renewal option, the option is not considered in determining the~~ lease ~~term,~~expense ~~and~~of ~~associated potential additional payments are excluded from lease payments~~$0.2 ~~The~~million ~~Company~~related ~~elected~~ to ~~account for each lease component and its associated non-lease components as a single lease component and has allocated all of~~ the ~~contract~~AZ ~~consideration across~~ lease ~~components only~~. The Company has ~~existing~~two ~~net~~additional operating leases inthat ~~which the non-lease components (e.g., common area maintenance)~~ are ~~paid separately from rent based on actual costs incurred and therefore are not~~ included in ~~the~~its ~~operating~~ lease ~~right-of-use~~accounting ~~assets~~which ~~and lease liabilities and~~ are ~~reflected~~not asconsidered ~~an expense in the period incurred~~significant.

The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets (in thousands):


	~~As of~~		~~As of~~
	~~September~~As 30of March 31, ~~2021~~2022		As of December 31, ~~2020~~2021
Assets
Operating lease right-of-use assets	$	~~744~~3,724	$	~~1,141~~604

Liabilities
Operating lease liabilities, current	$	~~681~~545	$	~~617~~704
Operating lease liabilities, net of current portion		~~183~~3,299		~~704~~-
Total operating lease liabilities	$	~~864~~3,844	$	~~1,321~~704

Future minimum lease payments under non-cancelable leases were as detailed below (in thousands):


Fiscal Year	As of ~~September~~March 3031, ~~2021~~2022
2021 (remaining 3 months)	$	179
2022 (remaining 9 months)	$	553
2022		737
2023		1,249
2023		1
2024		1,269
Total undiscounted lease payments		917
2025		1,289
Less: imputed interest		(53)
Total undiscounted lease payments		4,360
Total operating lease liabilities	$	864
Less: imputed interest		(516)
Total operating lease liabilities	$	3,844

As of ~~September~~March 3031, ~~2021~~2022, the weighted average remaining lease term was 1.3.8 years and the weighted-average incremental borrowing rate used to determine the operating lease right-of-use assets was 97.18%.

145. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):



	As of March 31, 2022			As of December 31, 2021
Accrued compensation and benefits	$	1,534	$	3,668
Accrued contract manufacturing		2,610		2,678
Accrued clinical		1,273		691
Current portion of operating lease liabilities		545		704
Accrued professional services		420		375
Accrued research		361		292
Accrued legal		341		55
Other		269		62
Total accrued expenses and other current liabilities	$	7,353	$	8,525

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

56. ~~Accrued~~Convertible ~~Expenses~~Note ~~and~~– ~~Other~~Related ~~Current Liabilities~~Party

Accrued expenses and other current liabilities consisted of the following (in thousands):


	As ofSeptember 30, 2021		As ofDecember 31, 2020
Accrued compensation and benefits	$	3,215	$	2,935
Accrued contract manufacturing		2,270		2,959
Accrued clinical		948		504
Current portion of operating lease liabilities		681		617
Accrued professional services		644		435
Accrued research		365		349
Other		95		106
Total accrued expenses and other current liabilities	$	8,218	$	7,905

On February 17, 2022, the Company entered into the Fourth Securities Purchase Agreement with a subsidiary of Innoviva, pursuant to which the Company issued and sold to Innoviva, in a private placement which closed on February 18, 2022, the Convertible Note having a principal amount of $15.0 million. The Convertible Note is convertible at maturity at the election of the Company or Innoviva into shares of the Company’s common stock at a conversion price of $1.48 per share of common stock and warrants to purchase an equal number of shares of Common Stock with an exercise price of $1.48 per share of common stock. As of March 31, 2022, the Convertible Note was convertible into 10,141,852 shares of common stock and 10,141,852 warrants. The Convertible Note will also be convertible at the option of Innoviva if the Company engages in certain capital markets transactions, asset sales or royalty transactions. If the Company is acquired prior to the maturity date of the Convertible Note, the Convertible Note will be payable in cash at the time of such acquisition. The Convertible Note will mature on August 18, 2022, or the Maturity Date, and bears interest at a rate of 0.59% per annum. From and including the Maturity Date, if not converted, the Convertible Note will bear interest at a rate of 10.00% per annum through, but excluding, the date of repayment or conversion of the Convertible Note.

6The Convertible Note and the Warrants will have provisions that preclude conversion or exercise, respectively, if such conversion or exercise would result in the issuance of more than 19.99% ~~Funding~~of ~~Arrangements~~the Company’s currently outstanding common stock in the aggregate prior to obtaining stockholder approval.

Management evaluated the accounting for the Convertible Note features under ASC 815 – Derivatives and Hedging and concluded that there are no embedded features requiring bifurcation and valuation as a derivative. Therefore, the note has been recorded as a short term liability on the Company’s balance sheet.

The carrying value of the Convertible Note consisted of the following (in thousands):



	As of March 31, 2022
Principal	$	15,000
Accrued interest		10
Carrying value of convertible note	$	15,010

7. Funding Arrangements

NIH

In June 2020, the Company entered into a contract with the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH, the NIH Contract, which was effective beginning July 1, 2020 and provides the Company with reimbursement of certain qualified expenses incurred. The initial award consisted of approximately $3.0 million, with the potential to increase up to $15.5 million, and will be used to develop novel molecules from the Company’s non-β-lactam inhibitor, or NBP, platform. Funding from the contract will support research towards developing molecules with expanded Gram-negative spectrum against antibiotic resistant bacterial pathogens including E. coli, Acinetobacter, Pseudomonas and Klebsiella. In July 2021, the Company successfully completed the first milestones for the program associated with the initial award and has been awarded the Option 1 Period of the program to proceed with further optimization, beginning August 1, 2021. This option consists of an additional $2.9 million, bringing the total award to $5.9 million. Through ~~September~~March 3031, ~~2021~~2022, the Company has received $23.59 million in payments and recorded $3.4.5 million of grant income under this contract. The contract will be accounted for in a way that is consistent with the Company’s Government Contracts and Grant Agreements accounting policy. See Note 2, Summary of Significant Accounting Policies - Government Contracts and Grant Agreements, to the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2021 for additional information.

The Company recognized grant income in connection with the NIH contract of $0.8 million and $2.1 million during the three and nine months ended September 30, 2021, respectively, and $0.7 million during the three and nine months ended September 30, 2020. As of September 30, 2021, and December 31, 2020 the Company’s receivables for unreimbursed, eligible costs incurred under the NIH contract totaled $0.9 million and $0.7 million, respectively, including both billed and unbilled amounts.14

CARB-X

In March 2017 and October 2017, the Company entered into funding arrangements with the Trustees of Boston University to utilize funds from the U.S. government through the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, program, in support of the Company’s ETX0282CPDP and ETX0462 programs. The amount of specified research expenditures of the Company that could be covered is $18.5 million from April 2017 through May 2023. Through September 30, 2021, the Company has received $11.0 million in payments and recorded $12.7 million of grant income under these funding arrangements. The remaining $5.8 million that could be received is related to the Company’s ETX0462 program.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

The Company recognized grant income in connection with the ~~CARB-X~~NIH ~~agreements~~Contract of $0.56 million and $20.47 million during the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021,~~2022 ~~respectively,~~ and ~~$0.8 million during the three and nine months ended September 30~~2021, ~~2020~~respectively. As of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020,~~2021 the Company’s receivables for unreimbursed, eligible costs incurred under the ~~CARB-X~~NIH ~~agreements~~contract totaled $2.0.5 million and $10.1 6 million, respectively, including both billed and unbilled amounts.

~~7. License and Collaboration Agreements~~CARB-X

In March 2017 and October 2017, the Company entered into funding arrangements with the Trustees of Boston University to utilize funds from the U.S. government through the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, program, in support of the Company’s ETX0282CPDP and ETX0462 programs. The amount of specified research expenditures of the Company that could be covered is $18.5 million from April 2017 through May 2023. Through March 31, 2022, the Company has received $12.6 million in payments and recorded $13.0 million of grant income under these funding arrangements. The remaining $5.9 million that could be received is related to the Company’s ETX0462 program.

The Company recognized grant income in connection with the CARB-X agreements of $0.1 million and $1.3 million during the three months ended March 31, 2022 and 2021. As of March 31, 2022 and December 31, 2021, the Company’s receivables for unreimbursed, eligible costs incurred under the CARB-X agreements totaled $0.7 million, including both billed and unbilled amounts.

8. License and Collaboration Agreements

GARDP

In July 2017, the Company entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership, or GARDP, for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries. Under the terms of the collaboration agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 ~~registration~~registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. The Phase 3 ~~registration~~registrational trial was initiated in September 2019 with activation of U.S. sites. The trial was negatively impacted by the COVID-19 pandemic, resulting in a 4-month pause in enrollment in mid-2020. Although GARDP resumed patient enrollment into the Phase 3 ~~registration~~registrational trial after the pause, any future impact by the continued COVID-19 pandemic at clinical trial sites cannot be estimated at this time. The Company has observed an increase in the enrollment rate during the past three quarters and now anticipates the Phase 3 trial to be fully enrolled in 2023.

In addition, under the collaboration agreement, the Company has granted GARDP a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use its zoliflodacin technology in connection with GARDP’s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. The Company has retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. The Company has also retained the right to use and grant licenses to its zoliflodacin technology to perform its obligations under the collaboration agreement and for any purpose other than gonorrhea or community-acquired indications. If the Company believes that the results of the Phase 3 ~~registration~~registrational trial of zoliflodacin would be supportive of an application for marketing approval, it is obligated to use its best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the EMA. Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

Zai Lab

In April 2018, the Company entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd., or Zai Lab, pursuant to which Zai Lab licensed exclusive rights to durlobactam and sulbactam-durlobactam, or SUL-DUR, in the Asia-Pacific region, or the Zai Agreement. Under the terms of the Zai Agreement, Zai Lab ~~will~~funded ~~fund~~ most of the Company’s clinical trial costs in China for SUL-DUR, including all costs in China for the Company’s Phase 3 ~~registration~~registrational trial of SUL-DUR, with the exception of Phase 3 patient drug supply. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. The Company is obligated to supply Zai Lab with the licensed products for clinical development, although Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.

The Company received an upfront, non-refundable payment of $5.0 million, milestone payments of $7.0 million, research support funding of $0.6 million and certain other reimbursable registrational trial costs of $5.9 million, less applicable taxes of $2.2 million, from Zai Lab through March 31, 2022. During the three months ended March 31, 2022 and 2021, the Company recognized no revenue under the Zai Agreement. The Company is eligible to receive up to an aggregate of $91.0 million in additional research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay the Company a tiered royalty equal from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Payments received for research support and reimbursable clinical trial costs are recorded as an offset to research and development expense during the period in which the qualifying expenses are incurred.

Future potential milestone payments were excluded from the initial transaction price as they were fully constrained as the risk of significant reversal of revenue had not yet been resolved. At the outset of the Zai Agreement, the achievement of the future potential milestones was not within the Company’s control and was subject to certain research and development success, regulatory approvals or commercial success and therefore carried significant uncertainty. The Company reevaluates the likelihood of achieving the future milestones at the end of each reporting period. Future development milestone revenue from the arrangement will be recognized as revenue in the period when it is no longer probable that revenue attributable to the milestone will result in a significant reversal of cumulative revenue.

9. Stockholders’ Equity and Stock-Based Compensation Expense

Common Stock

Each holder of common stock shall be entitled to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. Common stockholders are entitled to receive dividends when and if declared by the board of directors, out of any funds legally available. As of March 31, 2022, no dividends have been declared or paid.

Fourth Private Placement

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~The~~February ~~Company received an upfront~~18, ~~non-refundable payment of $5.0 million~~2022, milestone payments of $7.0 million, research support funding of $0.6 million and certain other reimbursable registration trial costs of $5.4 million, less applicable taxes of $2.2 million, from Zai Lab through September 30, 2021. During the ~~nine~~Convertible ~~months~~Note ~~ended~~having ~~September~~a ~~30,~~principal ~~2021~~amount ~~and 2020, the Company recognized no revenue under the Zai Agreement. The Company is eligible to receive up to an aggregate~~ of $9115.0 ~~million~~ ~~in additional research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products~~million. ~~Zai~~Refer ~~Lab will pay the Company a tiered royalty equal from a high-single digit~~ to ~~low-double~~Note ~~digit percentage~~6 ~~based on annual net sales of licensed products in the territory, subject to specified reductions~~ for ~~the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for~~ additional ~~rights~~information ~~necessary~~related to ~~commercialize licensed products in~~ the ~~territory.~~Convertible Payments received for research support and reimbursable clinical trial costs are recorded as an offset to research and development expense during the period in which the qualifying expenses are incurredNote.

The Company determined the $5.0 million non-refundable upfront payment was the entire transaction price at the outset of the Zai Agreement. All other future potential milestone payments were excluded from the transaction price as they were fully constrained as the risk of significant reversal of revenue had not yet been resolved. At the outset of the Zai Agreement, the achievement of the future potential milestones was not within the Company’s control and was subject to certain research and development success, regulatory approvals or commercial success and therefore carried significant uncertainty. The Company reevaluates the likelihood of achieving the future milestones at the end of each reporting period. Future development milestone revenue from the arrangement will be recognized as revenue in the period when it is no longer probable that revenue attributable to the milestone will result in a significant reversal of cumulative revenue.

8. Stockholders’ Equity and Stock-Based Compensation Expense

Third Private Placement

On May 3, 2021, the Company entered into the Third Securities Purchase Agreement, with a subsidiary of Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva up to 10,000,000 newly issued shares of common stock of the Company at $2.00 per share and warrants to purchase up to 10,000,000 shares of common stock, each with an exercise price per share of $2.00.

Third Private Placement occurred in two tranches. At the First Closing, which occurred on May 3, 2021, Innoviva purchased 3,731,025 shares of common stock and warrants to purchase 3,731,025 shares of common stock, for aggregate gross proceeds of $7.5 million. At the Second Closing, which occurred on June 11, 2021, Innoviva purchased the remaining 6,268,975 shares of common stock and warrants to purchase 6,268,975 shares of common stock, for aggregate gross proceeds of $12.5 million.

Second Private Placement

Under the Second Securities Purchase Agreement, the Company issued and sold to the investors, including Innoviva, in a private placement (i) 8,183,878 newly issued shares of common stock of the Company at $2.675 per share, (ii) warrants to purchase an aggregate of 9,345,794 shares of common stock with an exercise price of $2.675, and (iii) pre-funded warrants, in lieu of common stock, to purchase an aggregate of 1,161,916 shares of common stock, with an exercise price of $0.001 per share, resulting in aggregate gross proceeds of approximately $25.0 million. The closing of the Second Private Placement occurred on September 1, 2020.

The exercise price and the number of shares of common stock issuable upon exercise of each warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company’s common stock. Each warrant is exercisable from the date of issuance and has a term of five years.

First Private Placement

Under the First Securities Purchase Agreement, the Company issued and sold to Innoviva 14,000,000 shares of common stock of the Company at $2.50 per share, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price per share of $2.50.

The First Private Placement occurred in two tranches. At the closing of the first tranche, which occurred on April 22, 2020, Innoviva purchased 1,322,510 shares of common stock and warrants to purchase 1,322,510 shares of common stock, for aggregate gross proceeds of approximately $3.3 million. At the closing of the second tranche, which occurred on June 11, 2020, Innoviva purchased the remaining 12,677,490 shares of common stock and warrants to purchase 12,677,490 shares of the common stock for aggregate gross proceeds of approximately $31.7 million.

At the closing of the first tranche, Innoviva and the Company entered into an investor rights agreement, or the Investor Rights Agreement, which provides that for so long as Innoviva and its affiliates hold at least 15% of the outstanding shares of the Company’s common stock on a fully-diluted basis, Innoviva shall have the right to designate two directors to the board of directors of the Company, or the Board; and for so long as Innoviva and its affiliates hold at least 8% of the outstanding shares of the Company’s common stock on a fully-diluted basis, Innoviva shall have the right to designate one director to the Board, subject to certain qualifications and conditions in the Investor Rights Agreement. The Investor Rights Agreement also provides for rights for Innoviva to participate pro rata in future offerings of securities by the Company.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~The~~As ~~exercise~~a ~~price~~result ~~and~~of the ~~number~~closings of ~~shares of common stock issuable upon exercise of each warrant is subject to appropriate adjustments in~~ the ~~event~~four ofprivate ~~certain stock dividends and distributions~~placements, Innoviva ~~stock~~owns ~~splits,~~approximately ~~stock~~59.9% ~~combinations,~~of ~~reclassifications or similar events affecting~~ the Company’s outstanding common stock. ~~Each~~as ~~warrant~~of isMarch ~~exercisable~~31, ~~from~~2022 without the ~~date~~exercise of ~~issuance~~the ~~and has a term of five years~~warrants.

First Private Placement

Under the First Securities Purchase Agreement, the First Private Placement occurred in two tranches. At the closing of the first tranche, which occurred on April 22, 2020, Innoviva purchased 1,322,510 shares of common stock and warrants to purchase 1,322,510 shares of common stock, for aggregate gross proceeds of approximately $3.3 million. At the closing of the second tranche, which occurred on June 11, 2020, Innoviva purchased the remaining 12,677,490 shares of common stock and warrants to purchase 12,677,490 shares of the common stock for aggregate gross proceeds of approximately $31.7 million.

At the closing of the first tranche, Innoviva and the Company entered into an investors rights agreement, or the Investor Rights Agreement, which provides that for so long as Innoviva and its affiliates hold at least 15% of the outstanding shares of the Company’s common stock on a fully-diluted basis, Innoviva shall have the right to designate two directors to the board of directors of the Company, or the Board; and for so long as Innoviva and its affiliates hold at least 8% of the outstanding shares of the Company’s common stock on a fully-diluted basis, Innoviva shall have the right to designate one director to the Board, subject to certain qualifications and conditions in the Investor Rights Agreement. The Investor Rights Agreement also provides for participation rights for Innoviva to participate pro rata in future offerings of securities by the Company.

As a result of the closings of the three private placements, Innoviva owns approximately 60.6% of the Company’s outstanding common stock without the exercise of the warrants.

At-the-Market Facility

In August 2021, the Company entered into a Controlled Equity Offering Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co, or Cantor, for the offer and sale of up to $17.5 million of its common stock at the then current market prices in amounts to be determined from time to time. ~~There~~On October 21, 2021, the Company sold an aggregate of 200,000 shares of common stock at a sale price of $3.25 per share, for gross proceeds of $0.7 million. Proceeds, net of fees, were no$0.6 million. No sales ~~under~~of ~~this~~common ~~program~~stock ~~through~~have ~~September~~occurred ~~30,~~during ~~2021~~the first quarter of 2022 under the facility.

Warrants

As of ~~September~~March 3031, ~~2021~~2022, outstanding warrants to purchase shares of the Company’s common stock are as follows:


Shares Underlying Outstanding Warrants	Exercise Price		Expiration Date
1,322,510	$	2.50	April 22, 2025
12,677,490	$	2.50	June 11, 2025
8,672,897	$	2.675	September 1, 2025
10,000,000	$	2.00	May 3, 2026
32,672,897

The table above does not include the potential warrants associated with the Company’s $15.0 million Convertible Note with Innoviva. The Convertible Note is convertible at maturity at the election of the Company or Innoviva into shares of the Company’s common stock at a conversion price of $1.48 per share and warrants to purchase an equal number of shares of the Company’s common stock with an exercise price of $1.48 per share. As of March 31, 2022, the Convertible Note was convertible into 10,141,852 shares of common stock and 10,141,852 warrants. Refer to Note 6 – Convertible Note, for further details.

Stock Incentive Plan

In September 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Equity Incentive Plan, or the 2018 Plan, which became effective on September 25, 2018, at which point no further grants will be made under the 2015 Stock Incentive Plan, or the 2015 Plan. In June 2020, the Board adopted, and its stockholders approved, an amendment to the 2018 Plan, to increase the number of shares available for stock-based awards by 500,000. Under the 2018 Plan, the Company may grant incentive stock options, or ISOs, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. As of March 31, 2022, stock options to purchase an aggregate of 5,213,284 shares had been granted, restricted stock units, or RSUs, of 3,670,913 had been awarded, and 1,270,829 shares were available for future issuance under the 2018 Plan, as amended. The options issued under the 2018 Plan expire after 10 years from the grant date.

At its inception, the aggregate number of shares of the Company’s common stock available for issuance under the 2018 Plan was 2,350,000. The number of shares of the Company’s common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year, for a period of 10 years, from January 1, 2019 continuing through January 1, 2028, by 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. Accordingly, on January 1, 2022 and 2021, 1,914,071 and 1,465,494 shares were added to the number

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~Aspire~~of ~~Common~~available ~~Stock~~shares, ~~Purchase~~respectively. ~~Agreement~~The maximum number of shares that may be issued pursuant to the exercise of ISOs under the 2018 Plan is 7,500,000.

In October 2019, the Company entered into a common stock purchase agreement, or CSPA, with Aspire Capital Fund, LLC, or Aspire, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $20.0 million of shares of the Company’s common stock over the 30-month term of the CSPA. In advance of the Company’s entry into the Sales Agreement with Cantor, the Company and Aspire agreed to terminate the CSPA. The CSPA was terminated without liability of either party to the other.

Stock Incentive Plans

In September 2018, the Company’s board of directors adopted, and its stockholders approved the 2018 Equity Incentive Plan, or the 2018 Plan, which became effective on September 25, 2018, at which point no further grants will be made under the 2015 Stock Incentive Plan, or the 2015 Plan. In June 2020, the Board adopted, and its stockholders approved an amendment to the 2018 Plan, to increase the number of shares available for stock-based awards by 500,000. Under the 2018 Plan, the Company may grant incentive stock options, or ISOs, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. As of September 30, 2021, stock options to purchase an aggregate of 5,183,885 shares had been granted, restricted stock units, or RSUs, of 992,600 had been awarded, and 1,469,103 shares were available for future issuance under the 2018 Plan, as amended. The options issued under the 2018 Plan expire after 10 years from the grant date.

At its inception, the aggregate number of shares of the Company’s common stock available for issuance under the 2018 Plan was 2,350,000. The number of shares of the Company’s common stock reserved for issuance under the 2018 Plan automatically increases on January 1 of each year, for a period of 10 years, from January 1, 2019 continuing through January 1, 2028, by 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by Board. Accordingly, on January 1, 2021 and 2020, 1,465,494 and 531,662 shares were added to the number of available shares, respectively. The maximum number of shares that may be issued pursuant to the exercise of ISOs under the 2018 Plan is 7,500,000.

The maximum number of shares of the Company’s common stock subject to awards granted under the 2018 Plan or otherwise during a single calendar year to any nonemployee director, taken together with any cash fees paid by the Company to such nonemployee director during the calendar year for serving on the Board, will not exceed $500,000 in total value, or, with respect to the calendar year in which a nonemployee director is first appointed or elected to the Company’s board of directors, $800,000.

All options and awards granted under the 2015 Plan consisted of the Company’s common stock. As of September 25, 2018, no additional stock awards have been or will be granted under the 2015 Plan. Although the 2015 Plan was terminated as to future awards in September 2018, it continues to govern the terms of options that remain outstanding under the 2015 Plan.

Stock Option Activity

Stock option activity under both plans during the three months ended March 31, 2022 is summarized as follows:


				Weighted-
		Weighted-		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Contractual	Intrinsic
	Options	Price		Term (Years)	Value (in thousands)
Outstanding as of December 31, 2021	2,895,380	$	3.21	8.33	$	30
Granted	—
Forfeited and expired	(159,637)		2.98
Outstanding as of March 31, 2022	2,735,743	$	3.22	7.85	$	6
Exercisable as of March 31, 2022	1,011,812	$	3.89	5.85	$	2

Stock Option Exchange

On June 17, 2021, the Company commenced a voluntary stock option exchange program, or the Exchange Program, to permit the Company’s eligible employees, directors and certain consultants to exchange some or all of their eligible outstanding options, or the Original Options, to purchase the Company’s common stock with an exercise price greater than or equal to $4.98 per share, whether vested or unvested, for a lesser number of new stock options, or the New Options. The New Options will be granted under the 2018 Plan on the date on which the Original Options accepted for exchange are cancelled. Participants must remain continuously employed by the Company or in continuous service to the Company through the New Option grant date. New Options will have a per share exercise price equal to the per share closing price of the Company’s common stock on the New Option grant date. The New Options will have the same vesting schedule as the Original Options for options with a remaining vesting period exceeding 12 months. For Original Options with a remaining vesting period of 12 months or less, including full vesting options, the replacement options will vest in full 12 months from the New Option grant date. In accordance with the terms and conditions of the Exchange Program, the Company closed the exchange program and accepted all exchanged outstanding options on July 16, 2021, at which time the Company’s common stock price per share was $2.44. The stock option exchange program was approved at the Company’s annual shareholder meeting on June 10, 2021.

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

~~Stock~~Pursuant ~~Option~~to ~~Activity~~the Exchange Program, 44 eligible participants elected to exchange, and the Company accepted for cancellation Original Options to purchase an aggregate of 1,562,752 shares of the Company’s common stock, representing approximately 97% of the total shares of common stock underlying the eligible Original Options. On July 16, 2021, immediately following the expiration of the exchange offer, the Company granted New Options to purchase 1,148,572 shares of common stock, pursuant to the terms of the exchange offer and the Company’s 2018 Plan. In addition to the grant date fair value of the original awards, the Company will recognize incremental expense of approximately $0.3 million over the remaining service periods of the replacement awards.

Stock option activity under both plans during the nine months ended September 30, 2021 is summarized as follows:


				Weighted-
		Weighted-		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Contractual	Intrinsic
	Options	Price		Term (Years)	Value (in thousands)
Outstanding as of December 31, 2020	3,112,704	$	5.58	7.76	$	44
Granted	1,463,376		2.44
Forfeited and expired	(1,656,419)		6.97
Outstanding as of September 30, 2021	2,919,661	$	3.21	8.58	$	1,578
Exercisable as of September 30, 2021	923,730	$	3.86	6.75	$	115

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. During the nine months ended September 30, 2021, the weighted-average grant date fair value per granted option was $4.07. As described below, on July 16, 2016, the Company completed a stock option exchange program that resulted in the termination of options to purchase 1,562,752 shares of the Company’s common stock with a weighted-average exercise price of $7.17 per share and in exchange issued stock options to purchase 1,148,572 shares of the Company’s common stock with an exercise price of $2.44 per share.

Restricted Stock Unit Activity

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, the Company granted ~~597~~2,~~500~~678,313 RSUs to ~~executives~~employees and directors~~, of which 254,750 contained a performance condition~~. ~~As of September 30, 2021, the performance condition was not probable of being met.~~ Restricted stock unit activity for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 is summarized as follows:


		Weighted-
		Average
	Number of	Grant Date
	Units	Fair Value
Outstanding as of December 31, 2020	395,100	$	1.65
Outstanding as of December 31, 2021	490,975	$	2.20
Granted	~~597~~2,~~500~~678,313		21.5792
Forfeited	(48270,~~650~~600)		1.6597
Outstanding as of September 30, 2021	943,950	$	2.23
Outstanding as of March 31, 2022	2,898,688	$	1.96

Employee Stock Purchase Plan

In September 2018, the Company’s board of directors and its stockholders approved the 2018 Employee Stock Purchase Plan, or the ESPP, which became effective as of September 25, 2018. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 140,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2019 and ending in 2028, in each case subject to the approval of the board of directors, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 250,000 shares; provided, that prior to the date of any such increase, the board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). Pursuant to the terms of the 2018 Employee Stock Purchase Plan, an additional 250,000 shares were added to the number of available shares effective January 1, 2022 and 2021. As of March 31, 2022, no shares of common stock had been issued under the ESPP and 654,163 shares remained available for future issuance under the ESPP. No offering period under the ESPP has been set by the Company’s board of directors.

Stock-Based Compensation

Stock-based compensation expense was classified in the consolidated statement of operations as follows (in thousands):


	Three Months Ended
	March 31,
	2022		2021
Research and development	$	363	$	421
General and administrative		334		448
Total stock-based compensation expense	$	697	$	869

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

Employee Stock Purchase Plan

In September 2018, the Company’s board of directors and its stockholders approved the 2018 Employee Stock Purchase Plan, or the ESPP, which became effective as of September 25, 2018. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 140,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2019 and ending in 2028, in each case subject to the approval of the board of directors, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 250,000 shares; provided, that prior to the date of any such increase, the board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). Pursuant to the terms of the 2018 Employee Stock Purchase Plan, an additional 250,000 and 132,915 shares were added to the number of available shares effective January 1, 2021 and 2020, respectively. As of September 30, 2021, no shares of common stock had been issued under the ESPP and 654,163 shares remained available for future issuance under the ESPP. No offering period under the ESPP has been set by the Company’s board of directors.

Stock-Based Compensation

Stock-based compensation expense was classified in the consolidated statement of operations as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Research and development	$	449	$	330	$	1,293	$	1,027
General and administrative		469		334		1,376		1,172
Total stock-based compensation expense	$	918	$	664	$	2,669	$	2,199

The following table summarizes stock-based compensation by type of award (in thousands):

Three Months Ended

~~Nine Months Ended~~

~~September~~March 3031,

~~September 30,~~

~~2021~~2022

~~2020~~2021

~~2021~~

~~2020~~

Stock options

~~717~~247

~~664~~665

~~2,061~~

~~2,199~~

Restricted stock units

~~201~~450

—204

~~608~~

—

Total stock-based compensation expense

~~918~~697

~~664~~869

~~2,669~~

~~2,199~~

~~For~~The ~~the~~following ~~nine~~table ~~months~~summarizes ~~ended~~unrecognized ~~September~~stock-based 30compensation expense as of March 31, ~~2021~~2022, by type of awards, and the ~~restricted~~weighted-average ~~stock~~period ~~units~~over ~~performance~~which ~~obligation~~that ~~was~~expense ~~not~~is ~~probable~~expected ofto ~~being~~be ~~met,~~recognized. ~~and~~The astotal ~~such~~unrecognized nostock-based compensation expense ~~was~~will ~~recognized~~be adjusted for actual forfeitures as they occur.

The following table summarizes unrecognized stock-based compensation expense as of September 30, 2021, by type of awards, and the weighted-average period over which that expense is expected to be recognized. The total unrecognized stock-based compensation expense will be adjusted for actual forfeitures as they occur.


	As of ~~September~~March 3031, ~~2021~~2022
	Unrecognized Expense		Weighted-average Remaining Recognition Period
	(in thousands)		(in years)
Stock options	$	21,~~229~~558		1.9446
Restricted stock units	$	~~774~~4,838		03.8927

2110. Net Loss per Share

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

Stock Option Exchange

Pursuant to the Exchange Program, 44 eligible participants elected to exchange, and the Company accepted for cancellation Original Options to purchase an aggregate of 1,562,752 shares of the Company’s common stock, representing approximately 97% of the total shares of common stock underlying the eligible Original Options. On July 16, 2021, immediately following the expiration of the exchange offer, the Company granted New Options to purchase 1,148,572 shares of common stock, pursuant to the terms of the exchange offer and the Company’s 2018 Plan. In addition to the grant date fair value of the original awards, the Company will recognize incremental expense of approximately $0.3 M over the remaining service periods of the replacement awards.

9. Net Loss per Share

Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. The Company’s potentially dilutive shares, which include outstanding stock options and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following outstanding securities have been excluded from the computation of diluted weighted average shares outstanding for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021, as they would have been anti-dilutive:


	As of ~~September~~March 3031,
	~~2021~~2022	~~2020~~2021
Options to purchase shares of common stock	2,~~919~~735,~~661~~743	3,~~107~~049,~~671~~357
Warrants to purchase shares of common stock	32,672,897	2422,~~507~~672,~~710~~897
Unvested restricted stock units	~~943~~2,~~950~~898,688	—861,700
	36,536,508	27,615,381
Convertible note (1)	10,141,852	—
Convertible note warrants (1)	10,141,852	—
	58,591,032	26,583,954

10(1) Convertible Note common stock is calculated using the conversion price of $1.48 ~~Commitments~~per share and includes interest accrued as of March 31, 2022. Warrants issued upon conversion of the Convertible Note shall be equal to the common stock issued upon conversion.

11. Commitments

Lease Commitments

The Company has an operating lease agreement for its office and laboratory space with AstraZeneca. See Note 4, Leases, to these notes to consolidated financial statements for additional information.

2221

Table of Contents

ENTASIS THERAPEUTICS HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

AstraZeneca Subscription Agreement

In connection with the Company’s 2015 spin-out from AstraZeneca, the Company entered into a business transfer and subscription agreement with AstraZeneca pursuant to which the Company agreed to pay AstraZeneca a one-time milestone payment of $5.0 million within three months of achieving a specified cumulative net sales milestone for durlobactam. This milestone payment will be automatically waived should the Company’s common stock trade on The Nasdaq Global Market at or above a specified price at any time prior to achieving such specified cumulative net sales milestone for durlobactam. The Company is also obligated to pay AstraZeneca a one-time milestone payment of $10.0 million within two years of achieving the first commercial sale of zoliflodacin. At the Company’s election, either milestone payment may be paid in cash, common stock, or a combination of cash and common stock. Additionally, the Company is obligated to pay AstraZeneca tiered, single-digit, per-country royalties on the annual worldwide net sales of durlobactam and zoliflodacin.

1112. Related Party Transactions

Innoviva

On February 17, 2022, the Company entered into the Fourth Securities Purchase Agreement with a subsidiary of Innoviva, the Company’s majority shareholder, pursuant to which the Company issued and sold to Innoviva, in a private placement which closed on February 18, 2022, the Convertible Note having a principal amount of $15.0 million. The Convertible Note is convertible at maturity at the election of the Company or Innoviva into shares of the Company’s common stock at a conversion price of $1.48 per share of common stock and warrants to purchase an equal number of shares of Common Stock with an exercise price of $1.48 per share of common stock. See Note 6, Convertible Note, to these notes to consolidated financial statements for additional information.

AstraZeneca

The Company was formed in May 2015 as a wholly owned subsidiary of AstraZeneca. Prior to the closing of the initial public offering on September 28, 2018, AstraZeneca was the sole series A preferred stockholder. Upon the closing of the initial public offering, all shares of preferred stock were converted into shares of common stock of the Company. AstraZeneca continues to maintain an ownership interest in the Company. The Company has an operating lease agreement for its office and laboratory space with AstraZeneca. See Note 4, Leases, to these notes to consolidated financial statements for additional information.

Pharmaron Beijing Co., Ltd. (China)

The Company contracts with Pharmaron Beijing Co., Ltd. (China), or Pharmaron, to provide various medicinal chemistry research, manufacturing development and clinical services related to the Company’s ongoing product candidates. The Company began utilizing Pharmaron as a service provider prior to the spin-out in 2015 ~~(see Note 1~~, ~~Organization~~ and ~~Description of Business, to these notes to consolidated financial statements for additional information), and~~ this relationship has continued ~~into~~through ~~2021~~2020. In 2019, the Senior Vice President of Strategic Partnerships at Pharmaron began sharing a household with the Company’s Chief Executive Officer, and, as a result, the Company considers the agreements between the Company and Pharmaron to be related-party transactions. The Company recorded expense of $1.59 million and $2.1.2 million during the three months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020, respectively, and $3.0 million and $3.4 million during the nine months ended September 30,~~ 2021 ~~and 2020~~, respectively, for services rendered pursuant to multiple Pharmaron agreements. Amounts due to Pharmaron were $1.0 ~~million and $2~~.01 million as of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020, respectively~~2021.

2322

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited consolidated financial information and the notes thereto included in this Quarterly Report on Form 10-Q and with our audited consolidated financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021, which was filed with the SEC on March 233, ~~2021~~2022, or the Annual Report on Form 10-K. In addition, you should read the “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are an advanced, late clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted antibacterial products that address high unmet medical needs to treat serious infections caused by multidrug-resistant pathogens. On February 1, 2022, our Board of Directors received a preliminary, non-binding proposal from our majority stockholder, Innoviva Inc., or Innoviva, to acquire all the outstanding equity securities of the Company that are not currently owned by Innoviva for a per share consideration of $1.80, payable in cash. On March 15, 2022 Innoviva revised its non-binding offer to acquire the Company to increase the purchase thereunder to $2.00 per share in cash. All other terms of the offer remain unchanged. The offer letter and amended offer letter delivered by Innoviva to our Board of Directors are publicly available in the Schedule 13D amendments dated February 1, 2022 and March 15, 2022, respectively, filed by Innoviva with the SEC. Our Board of Directors, which does not include any members appointed by or affiliated with Innoviva, has retained MTS Health Partners, L.P. and Covington & Burling, LLP to explore alternatives and to assist the Board of Directors in its evaluation of the proposal consistent with its fiduciary duties.

Our lead product candidate, sulbactam-durlobactam, or SUL-DUR, is an intravenous, or IV, combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor, or BLI, that we are developing for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii, or Acinetobacter. Based on current carbapenem resistance rates, we estimate there are in excess of ~~200~~250,000 hospital-treated carbapenem-resistant Acinetobacter infections annually across the United States, Europe, the Middle East and China for which significant morbidity and mortality exists due to limited treatment options. We initiated ATTACK (Acinetobacter Treatment Trial Against Colistin), our single Phase  3 ~~registration~~registrational trial, in ~~April~~ 2019, and announced positive top-line Phase 3 data in October 2021 demonstrating that the primary efficacy and safety objectives had been achieved. ~~ATTACK~~Specifically, ~~enrolled~~the ~~207~~results indicated non-inferiority in 28-day all-cause mortality in patients atwith 95carbapenem-resistant Acinetobacter infections and a statistically significant higher clinical ~~sites~~cure inrate 16compared ~~countries~~to colistin. ~~This~~SUL-DUR ~~was~~also had a ~~two-part~~favorable ~~trial~~safety profile when compared to colistin with ~~Part~~a Astatistically ~~being~~significant reduction in nephrotoxicity. Based on the ~~randomized,~~success ~~comparative~~of ~~portion~~ATTACK (and the totality of the SUL-DUR vspreclinical ~~colistin)~~and inclinical ~~patients~~data, we also announced our intention to file a new drug application, or NDA, with ~~documented~~the ~~Acinetobacter~~U.S. ~~hospital-acquired~~Food ~~bacterial~~& ~~pneumonia~~Drug ~~(HABP)~~Administration, ~~ventilator~~or FDA, in mid-~~associated~~2022. SUL-DUR ~~bacterial~~has ~~pneumonia~~been ~~(VABP)~~awarded Fast Track status designation providing potential eligibility for accelerated approval and priority review, ~~ventilated~~if ~~pneumonia~~relevant criteria are met, following acceptance of our submission by the FDA. With the support of our partner Zai Lab (VPShanghai) Co., Ltd. or ~~bacteremia~~Zai Lab (Nasdaq: ZLAB), we enrolled approximately 25% of the ATTACK trial in China and ~~Part~~combined Bwith ~~being~~the anstrength ~~open~~of the overall SUL-~~labeled~~DUR ~~portion~~data ~~including~~set, ~~Acinetobacter~~we ~~infections~~believe ~~resistant~~the todata orwill ~~failed~~also ~~colistin~~support ora ~~polymyxin~~regulatory Bsubmission ~~treatment~~in China. ~~Baseline~~Zai ~~Acinetobacter~~Lab ~~isolates~~has ~~tested~~an ~~were~~exclusive ~~95%~~license ~~carbapenem~~to ~~resistant~~develop and commercialize SUL-DUR in mainland China as well as the broader Asia-Pacific region.

~~SUL-DUR~~Our ~~met~~second ~~the~~late-stage ~~primary~~product ~~efficacy~~candidate, ~~endpoint~~zoliflodacin, ofis ~~28-day~~a ~~all-cause~~novel ~~mortality~~orally ~~compared~~administered tomolecule ~~colistin~~being indeveloped for the ~~CRABC~~treatment ~~m-MITT population~~ of ~~Part~~uncomplicated Agonorrhea. ~~SUL-DUR~~The ~~mortality~~bacterial ~~was~~pathogen ~~19.0%~~responsible ~~(12/63)~~for ~~compared~~gonorrhea tois ~~32.3%~~Neisseria ~~(20/62)~~gonorrhoeae, inor ~~the~~N. ~~colistin~~gonorrhoeae, ~~arm~~including ~~(treatment~~multidrug-resistant ~~difference~~strains. Intramuscular injections of ~~-13.2%;~~ceftriaxone ~~95%~~now ~~CI:~~represent ~~-30.0,~~the 3only U.5)S. ~~Similar~~ ~~trends~~Centers ~~were~~for ~~demonstrated~~Disease inControl ~~28-day~~ and ~~14-day~~Prevention, ~~all-cause~~or ~~mortality~~CDC, ~~favoring~~recommended ~~SUL-DUR~~treatment ~~across~~option ~~all~~for ~~study~~the ~~populations~~estimated ~~evaluated to date~~1.6 Amillion ~~statistically~~annual ~~significant~~cases ~~difference~~of gonorrhea in ~~clinical~~the ~~cure~~United atStates. ~~Test~~We ofbelieve ~~Cure~~there ~~(TOC)~~is ~~was~~a ~~observed~~growing ~~with~~unmet ~~61.9%~~need infor ~~SUL~~a single-~~DUR~~dose ~~arm~~oral ~~compared~~antibiotic tothat ~~40.3%~~will inreliably ~~the~~treat ~~colistin~~patients ~~arm~~with ~~(95%~~gonorrhea, CIincluding ~~2.9~~infections caused by multidrug-40resistant strains of N.3) gonorrhoeae, which are emerging globally. InThe ~~Part~~Phase B3 registrational trial, ~~the~~initiated ~~28-day~~in ~~all-cause~~September ~~mortality~~2019, ~~was~~is ~~17.9%~~sponsored ~~(5/28)~~by ~~and~~our ~~consistent~~nonprofit ~~with~~collaborator, ~~that~~the ~~observed~~Global ~~in Part~~Antibiotic A.Research and Development Partnership, or

Safety analyses from a total of 177 patients suggested that SUL-DUR was generally well-tolerated with a favorable safety profile compared to colistin. SUL-DUR met the primary safety objective with a statistically significant reduction in nephrotoxicity as measured by the RIFLE classification. SUL-DUR nephrotoxicity was 13.2% (12/91) versus 37.6% (32/85) in the colistin arm (p = 0. 0002). Overall adverse events (AEs) in the safety population were comparable between treatment groups with 87.9% (80/91) in the SUL-DUR arm vs. 94.2% (81/86) in the colistin arm in Part A, 89.3% (25/28) in Part B. Drug related AEs were 12.1% (10.7% in Part B) with SUL-DUR compared to 30.2% with colistin. The most common non-infectious AEs (≥10%) in the SUL-DUR arm were diarrhea (16.5%), allergic and hypersensitivity reactions (16.5%), anemia (13.2%) and hypokalemia (12.1%) in Part A. These AEs were also >10% in the colistin arm as was acute kidney injury. 23

We believe that the data from the ATTACK trial, data from our other clinical trials of SUL-DUR and non-clinical data will be sufficient to submit an NDA to the FDA.

Table of Contents

~~Our second late-stage product candidate~~GARDP, ~~zoliflodacin,~~which isas ~~a novel orally administered molecule being developed for~~ the ~~treatment~~sponsor ofis ~~uncomplicated~~also ~~gonorrhea. The bacterial pathogen~~ responsible for ~~gonorrhea~~all isPhase ~~Neisseria-~~3 ~~gonorrhoeae,~~clinical ~~including~~trial ~~multidrug-resistant strains. Intramuscular injection of ceftriaxone now represents the only U.S. Centers for Disease Control~~ and ~~Prevention,~~pharmaceutical ordevelopment ~~CDC, recommended treatment option for the estimated 1~~expenses.6 ~~million~~GARDP ~~annual~~has ~~cases~~commercial ofrights ~~gonorrhea~~to zoliflodacin in ~~the~~up ~~United~~to ~~States.~~168 ~~We believe there is a growing unmet need for a single~~low-~~dose~~ ~~oral~~and ~~antibiotic~~select ~~that will reliably treat patients with gonorrhea, including infections caused by multidrug~~middle-~~resistant~~income ~~strains of N. gonorrhoeae~~countries, ~~which~~while ~~are~~Entasis ~~emerging~~retains ~~globally.~~commercial ~~The~~rights ~~Phase 3 registration trial, initiated~~ in ~~September~~the ~~2019,~~major ismarkets ~~a multi-center, open-label, noninferiority trial~~ in ~~approximately~~North 1America,~~000~~ ~~enrolled~~Europe ~~patients with uncomplicated gonorrhea. Our nonprofit collaborator, GARDP, is the sponsor of the registration trial~~ and ~~is responsible for all trial expenses~~Asia-Pacific. AsBased ofon ~~September~~current 30, 2021, 12 clinical trial sites across the U.S., Netherlands, South Africa and Thailand, are activated and actively enrolling patients. Despite the ongoing challenges with the COVID-19 pandemic, we have observed an increase in the enrollment ~~rate during the past quarter~~rates, ~~however~~ we ~~currently~~anticipate ~~remain unable to provide guidance around~~ the ~~timeline for completion of the Phase 3 registration~~ trial. Into consultation with GARDP we will provide more detailed guidance when appropriate. We believe data from the Phase 3 registration trial, along with data from our other clinical trials of zoliflodacin and non-clinical data will be ~~sufficient~~fully ~~for~~enrolled ~~submitting~~in ~~an NDA to the FDA~~2023.

WeOur ~~are~~third ~~also~~product ~~developing~~candidate is ETX0282CPDP ~~for~~which ~~the~~is ~~treatment~~a combination of a novel, oral BLI, ETX0282, with cefpodoxime proxetil or CPDP, which has the potential to address complicated urinary tract infections, or cUTIs, including those caused by multidrug-resistant Enterobacteriaceae. ~~ETX0282CPDP is an oral combination of ETX0282 with cefpodoxime proxetil.~~ We believe there is a significant unmet need for new oral antibiotics to reliably treat the estimated 3 to 4 million patients diagnosed annually with cUTIs. We have reported preliminary Phase 1 trial results, and ~~subsequently~~we ~~demonstrated~~are ~~that~~now anseeking ~~extended~~a ~~release~~partner ~~tablet~~to ~~formulation~~help ~~achieved~~further ~~preclinical~~advance ~~proof-of-concept~~ETX0282CPDP ofthrough ~~the~~additional ~~desired~~clinical ~~pharmacokinetic profile both in vitro and in non-human primates~~trials. ~~Having~~This ~~successfully~~program ~~completed~~was ~~the~~previously ~~initial~~supported ~~Phase~~by ~~1 studies and preclinical work to deliver a formulation with~~ the ~~desired~~Combating ~~extended~~Antibiotic ~~release~~Resistant ~~profile,~~Bacteria weBiopharmaceutical ~~are~~Accelerator ~~currently prioritizing our resources on preparing for NDA submission and supporting the ongoing Phase 3 registration trial for zoliflodacin~~program, ~~while~~or ~~we evaluate options for further clinical development of ETX0282CPDP~~CARB-X.

~~Lastly,~~We we are also advancing the development of a novel class of antibiotics, non- β-lactam inhibitors of penicillin -binding proteins, or NBPs. We believe NBPs constitute a potential new class of Gram-negative antibacterial agents that are designed to target a broad spectrum of multidrug resistant bacterial pathogens that overcome the main source of β-lactam resistance which is driven by β-lactamase activity. This novel class of agents is designed to potentially target a broad spectrum of multidrug resistant bacterial pathogens that are part of the CDC/World Health Organization, or WHO, list of high unmet medical need or ESKAPE pathogens. We selected ETX0462 as the initial clinical candidate for this program, aand ~~novel diazabicyclooctane~~ with ~~antimicrobial~~support ~~activity~~from ~~against multiple Gram~~CARB-~~negative~~X ~~pathogens~~we ~~including Pseudomonas aeruginosa as well as a number of high-priority biothreat pathogens. We~~ are currently working to complete ~~the~~additional ~~required~~ pre-clinical activities to enable the program to advance into a Phase 1 clinical trial. In June 2020, we were awarded a contract from the National ~~Institute~~Institutes of Health, or NIH, to support research towards developing additional NBP molecules with expanded Gram-negative spectrum from this novel class. This research program, designated NBP2, is attempting to target Klebsiella, Pseudomonas and E. coli from the ESKAPE list of pathogens. In July 2021, we successfully completed the first milestones for the program and have been awarded the Option 1 Period of the program to proceed with further optimization, beginning August 1, 2021. Subject to achieving pre-defined milestones, the contract is expected to sufficiently fund activities to achieve submission of an Investigational New Drug, or IND, application to the FDA. ~~To date, the COVID-19 pandemic has only impacted the status of our product candidates, SUL-DUR and zoliflodacin. It has not impacted the status of our other product candidates.~~

25Since our inception in May 2015, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, conducting discovery and development activities for our programs and planning for potential commercialization. We do not have any products approved for sale and have not generated any revenue from product sales. As of March 31, 2022, we have funded our operations primarily with net cash proceeds of $104.2 million from the sale of our preferred stock, net cash proceeds of $65.6 million from the sale of common stock in our initial public offering, and net cash proceeds of $93.5 million from the sale of common stock, warrants and pre-funded warrants in private placements, at-the-market sales and the issuance of a convertible note. We have also either directly received funding or financial commitments from, or have had our program activities conducted and funded by, the U.S. government through our arrangements with NIAID, CARB-X, and the U.S. Department of Defense, or DOD, and we have received non-profit awards from GARDP and upfront and milestone payments from our license and collaboration agreement with Zai Lab.

Table of Contents

Since our inception in May 2015, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, conducting discovery and development activities for our programs and planning for potential commercialization. We do not have any products approved for sale and have not generated any revenue from product sales. As of September 30, 2021, we have funded our operations primarily with net cash proceeds of $104.2 million from the sale of our preferred stock, net cash proceeds of $65.6 million from the sale of common stock in our initial public offering, and net cash proceeds of $77.9 million from the sale of common stock, warrants and pre-funded warrants in private placements to certain investors in 2020 and 2021. We have also either directly received funding or financial commitments from, or have had our program activities conducted and funded by, the U.S. government through our arrangements with NIAID, CARB-X, and the U.S. Department of Defense, or DOD, and we have received non-profit awards from GARDP and upfront and milestone payments from our license and collaboration agreement with Zai Lab.

Funding Arrangements

NIH

In June 2020, we entered into a contract with NIAID, part of the NIH, with an effective date of July 1, 2020. The contract consists of an initial award of approximately $3.0 million, with the potential to increase it up to $15.5 million, that will be used to develop novel molecules from our NBP platform. In July 2021, we successfully completed the first milestones for the program associated with the initial award and have been awarded the Option 1 Period of the program to proceed with further optimization, beginning August 1, 2021. This option consists of ~~any~~an additional $2.9 million, bringing the total award to $5.9 million. Funding from the contract will support research towards developing molecules with expanded Gram-negative spectrum against antibiotic-resistant bacterial pathogens including E. coli, Acinetobacter, Pseudomonas and Klebsiella. Through ~~September~~March 3031, ~~2021~~2022, we had received $23.5 9 million in payments and we ~~have~~had recorded $3.4 .5 million of grant income under this funding arrangement.

Table of Contents

CARB-X

In March 2017 and October 2017, we entered into funding arrangements with the Trustees of Boston University to utilize funds from the U.S. government, through the CARB-X program, for support of our ETX0282CPDP and ETX0462 programs. These funding arrangements could cover up to $18.5 million of our specified research expenditures from April 2017 through May 2023. Through ~~September~~March 3031, ~~2021~~2022, we had received $1112.0 6 million in payments and we have recorded $1213.70 million of grant income under these funding arrangements. The remaining $7.5.9 million of grant income that could be ~~received~~recorded is related to our ETX0462 program.

License and Collaboration Agreements

GARDP

In July 2017, we entered into a collaboration agreement with GARDP for the development and commercialization of a product candidate containing zoliflodacin in certain countries. Under the terms of the collaboration agreement, GARDP will fully fund the ongoing Phase 3 ~~registration~~registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea.

Zai Lab

In April 2018, we entered into a license and collaboration agreement with Zai Lab pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR in the Asia-Pacific region. Under the terms of the agreement, Zai Lab will fund most of our ~~registration~~registrational trial costs in China for SUL-DUR, with the exception of a Phase 3 patient drug supply of licensed product. As of ~~September~~March 3031, ~~2021~~2022, we have received net payments of $15.9 8 million, representing the $5.0 million upfront payment, $7.0 million of milestone payments, $0.6 million of research support payments and $5.49 million of certain other reimbursable ~~registration~~registrational trial costs, less applicable taxes of $2.2 million, from Zai Lab and we have recognized revenue of $12.0 million under this agreement.

Table of Contents

Components of Results of Operations

Revenue

All of our revenue has been derived from our license and collaboration arrangement with Zai Lab. To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates and preclinical program are successful and result in regulatory approval, we may generate revenue in the future from product sales.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our preclinical and clinical product candidates. These expenses include:

● employee-related expenses, including salaries and benefits, ~~bonus~~travel and stock-based compensation expense for employees engaged in research and development functions;

●

fees paid to consultants for services directly related to our product development and regulatory efforts;

● expenses incurred under agreements with contract research organizations, or CROs, as well as contract manufacturing organizations, or CMOs, and consultants that ~~conduct and~~ provide ~~supplies~~supporting activities for our preclinical studies, ~~and~~ clinical trials and NDA filing and approval efforts;

●

costs associated with preclinical activities and development activities;

● costs associated with our technology and our intellectual property portfolio;

●

costs related to compliance with regulatory requirements; and

●

facilities-related expenses, which include allocated rent and maintenance of facilities and other operating costs.

Costs associated with research and development activities are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.25

Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and preclinical programs and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under service, license or option agreements. We do not allocate employee costs or facility expenses to specific programs because these costs are deployed across multiple programs and, accordingly, are not separately classified. We primarily use internal resources and our own employees for managing our preclinical development, process development, manufacturing and clinical development activities.

Table of Contents

ToCosts ~~date,~~associated ~~substantially~~with ~~all~~research ofand ~~our~~development ~~research~~activities ~~and~~are expensed as incurred. Costs for certain development ~~expenses~~activities, ~~have~~such ~~been~~as ~~related~~clinical totrials, are recognized based on an evaluation of the ~~preclinical~~progress ~~and~~to completion of specific tasks using data such as patient enrollment, clinical ~~development~~site ofactivations ~~our~~or ~~product~~other ~~candidates~~information ~~and~~provided ~~preclinical~~to ~~program~~us by our vendors. ~~The~~Nonrefundable ~~following~~advance ~~table~~payments ~~shows~~for ~~our~~goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. bySuch ~~development~~amounts ~~program~~are ~~and~~recognized ~~type~~as ofan ~~activity:~~expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
	(in thousands)				(in thousands)
Direct research and development expenses by program:
SUL-DUR	$	4,672	$	5,207	$	13,754	$	18,771
Zoliflodacin		16		19		11		31
ETX0282CPDP		—		—		115		30
ETX0462		405		635		2,172		840
Other preclinical programs		193		137		592		523
Unallocated research and development expenses:
Personnel related (including stock-based compensation)		3,416		2,836		10,272		9,292
Facilities, supplies and other		580		553		1,722		1,762
Total research and development expenses	$	9,282	$	9,387	$	28,638	$	31,249

Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and preclinical program and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under service, license or option agreements. We do not allocate employee costs or facility expenses to specific programs for financial reporting purposes because these costs are deployed across multiple programs and, accordingly, are not separately classified. We primarily use internal resources and our own employees to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities.

To date, substantially all of our research and development expenses have been related to the preclinical and clinical development of our product candidates and preclinical programs. The following table shows our research and development expenses by development program and type of activity for the three months ended March 31, 2022 and 2021:


	Three Months Ended
	March 31,
	2022		2021

	(in thousands)
Direct research and development expenses by program:
SUL-DUR	$	5,639	$	4,030
ETX0462		95		1,192
ETX0282CPDP		4		60
Zoliflodacin		—		—
Other preclinical programs		637		216
Unallocated research and development expenses:
Personnel related (including stock-based compensation)		4,005		3,337
Facilities, supplies and other		612		535
Total research and development expenses	$	10,992	$	9,370

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

The duration, costs and timing of clinical trials and development of our product candidates and preclinical program will depend on a variety of factors that include, but are not limited to, the following:

● the impact of COVID-19 on ~~clinical~~hospitals ~~trial sites~~ participating in ~~our~~the trials and their ability to focus on and direct resources to our trials;

●

the number of trials required for approval and any requirement for extension trials;

Table of Contents

●

per-patient trial costs;

●

the number of patients that participate in the trials;

●

the number of sites included in the trials;

●

the countries in which the trials are conducted;

●

the length of time required to enroll eligible patients;

●

the number of doses that patients receive;

●

the drop-out or discontinuation rates of patients;

●

potential additional safety monitoring or other studies requested by regulatory agencies;

●

the duration of patient follow-up; and

Table of Contents

●

the efficacy and safety profiles of the product candidates.

Any changes in the outcome of any of these factors with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing and supply, and commercial viability. We will determine which programs to pursue and how much to fund each program based on the scientific and clinical success of each product candidate, as well as an assessment of each candidate’s commercial potential.

General and Administrative Expenses

General and administrative expenses consist of salaries and benefits and stock-based compensation expense for personnel in executive, finance and administrative functions. General and administrative costs also include facilities-related costs not otherwise included in research and development expenses asand ~~well as~~ professional fees for legal, patent, consulting, accounting, insurance and audit services.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research, development and commercialization activities of our product candidates. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing functions for that product candidate.

Other Income, Net

Grant Income

Grant income consists of income recognized in connection with grants we received under our funding arrangements with the Trustees of Boston University through the CARB-X program, as well as amounts received under our NIH ~~Contract~~contract. Grant income is recognized in the period during which the related specified expenses are incurred.

Interest Income

Interest income consists of interest earned on our cash and investment balances, which are primarily held in money market funds and U.S. Treasury Securities.

Table of Contents

Interest Expense

Interest expense consists of interest expense related to our convertible note.

Results of Operations

Comparison of the Three Months Ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021

The following table summarizes our results of operations for the periods presented:


	Three Months Ended ~~September~~March 3031,
	~~2021~~2022		~~2020~~2021		$ Change
	(in thousands)
Operating expenses:
Research and development	$	910,~~282~~992	$	9,~~387~~370	$	~~(105)~~1,622
General and administrative		4,~~320~~936		3,~~213~~307		1,~~107~~629
Total operating expenses		1315,~~602~~928		12,~~600~~677		13,~~002~~251
Loss from operations		(1315,~~602~~928)		(12,~~600~~677)		(13,~~002~~251)
Other income:
Other income, net:
Grant income		~~1,208~~672		1,~~458~~972		(~~250~~1,300)
Interest income		34		94		~~(6)~~—
Total other income		1,211		1,467		(256)
Interest expense		(10)		—		(10)
Net loss	$	(12,391)	$	(11,133)	$	(1,258)
Total other income, net		666		1,976		(1,310)
Net loss	$	(15,262)	$	(10,701)	$	(4,561)

Table of Contents

Research and Development Expenses

Research and development expenses were $911.30 million during the three months ended ~~September~~March 3031, ~~2021~~2022, compared to $9.4 million during the three months ended ~~September~~March 3031, ~~2020~~2021. The ~~decrease~~increase of $0.1.6 million was primarily due to aan ~~decrease~~increase of $01.56 million in expenses related to our SUL-DUR product candidate, ~~and~~an aincrease ~~decrease~~ of $0.27 million in personnel expenses ~~related~~and toan ~~our~~increase ~~ETX0462~~of ~~product~~$0.4 ~~candidate~~million in other preclinical programs, partially offset by ana ~~increase~~decrease of $01.61 million in ~~personnel~~ expenses related to our ETX0462 product candidate. The ~~decrease~~increase of $01.56 million in expenses related to our SUL-DUR product candidate was primarily due to aan ~~decrease~~increase of $0.3.2 million in ~~clinical~~manufacturing ~~trial~~ costs and an increase of $1.0 million in NDA support, partially offset by a decrease of $2.36 million in ~~manufacturing~~clinical trial costs. The decrease of $01.21 million in expenses related to our ETX0462 product candidate was due to a decrease of $01.21 million in manufacturing costs.

General and Administrative Expenses

General and administrative expenses were $4.39 million during the three months ended ~~September~~March 3031, ~~2021~~2022, compared to $3.23 million during the three months ended ~~September~~March 3031, ~~2020~~2021. The increase of $1.16 million was driven primarily by increases of $01.31 million in ~~legal~~consulting costs, $0.34 million in ~~personnel~~legal costs, ~~$0.2 million in consulting costs~~ and $0.1 million in ~~insurance~~investor ~~related~~and public relations costs.

Other Income, Net

Other income, net was $10.27 million during the three months ended ~~September~~March 3031, ~~2021~~2022, compared to $12.50 million during the three months ended ~~September~~March 3031, ~~2020~~2021. The decrease of $01.3 million was primarily due to a decrease of $01.3 million in grant income associated with our agreements with CARB-X and NIH.

~~Comparison of the Nine Months Ended September 30, 2021 and 2020~~28

The following table summarizes our results of operations for the periods presented:


	Nine Months Ended September 30,
	2021		2020		$ Change
	(in thousands)
Operating expenses:
Research and development		28,638		31,249		(2,611)
General and administrative		10,938		10,235		703
Total operating expenses		39,576		41,484		(1,908)
Loss from operations		(39,576)		(41,484)		1,908
Other income:
Grant income		4,444		1,519		2,925
Interest income		10		170		(160)
Total other income		4,454		1,689		2,765
Net loss	$	(35,122)	$	(39,795)	$	4,673

Research and Development Expenses

Research and development expenses were $28.6 million during the nine months ended September 30, 2021, compared to $31.2 million during the nine months ended September 30, 2020. The decrease of $2.6 million was primarily due to a decrease of $5.0 million in expenses related to our SUL-DUR product candidate, partially offset by increases of $1.3 million in expenses related to our ETX0462 product candidate and $1.0 million in personnel expenses. The decrease of $5.0 million in expenses related to our SUL-DUR product candidate was primarily due to decreases of $3.5 million in clinical trial costs and $1.2 million in manufacturing costs. The increase of $1.3 million in expenses related to our ETX0462 product candidate was due to an increase of $1.3 million in manufacturing costs.

Table of Contents

General and Administrative Expenses

General and administrative expenses were $10.9 million during the nine months ended September 30, 2021, compared to $10.2 million during the nine months ended September 30, 2020. The increase of $0.7 million was driven primarily by increases of $0.4 million in insurance expenses and $0.3 million professional services costs.

Other Income

Other income was $4.5 million during the nine months ended September 30, 2021, compared to $1.7 million during the nine months ended September 30, 2020. The increase of $2.8 million was due to an increase of $3.0 million in grant income associated with our agreements with CARB-X and NIH, offset by a decrease of $0.2 million in interest income.

Liquidity and Capital Resources

Overview

As of ~~September~~March 3031, ~~2021~~2022, we had cash and cash equivalents of $4433.15 million. We have funded our operations to date with the proceeds from equity securities offerings and the issuance of a convertible promissory note. In addition, we also have received funding or financial commitments from, or have had our program activities conducted and funded by, the U.S. government through arrangements with NIAID, CARB-X, NIH and the U.S. Department of Defense, and have received non-profit awards from GARDP and upfront milestone and cost reimbursement payments from Zai Lab.

Going Concern

Since our inception, we have incurred recurring losses and negative cash flows from operations. Our net loss was $3515.13 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 and $5047.51 million for the year ended December 31, ~~2020~~2021. As of ~~September~~March 3031, ~~2021~~2022, we had an accumulated deficit of $~~219~~246.69 million. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the necessary development, obtaining regulatory approval and preparing for potential commercialization of our product candidates. Based on our current operating plan, we ~~do not~~ believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through the third quarter of 2022 ~~however we believe it will be sufficient to fund our operating expenses and capital expense requirements into the second quarter of 2022~~. These conditions and events raise substantial doubt about our ability to continue as a going concern for the one-year period following the issuance of our consolidated financial statements for the quarter ended September 30, 2021. To finance our operations beyond this point, we will need to raise additional capital, which cannot be assured. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders will be further diluted, which dilution may be significant such as our recent issuance and sale of our common stock to Innoviva, Inc., or Innoviva. See Note 1, Organization and Description of Business, and Note 8, Stockholders’ Equity and Stock Based Compensation Expense, in the accompanying notes to our unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for additional information on our assessment. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern and that contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

These conditions and events raise substantial doubt about our ability to continue as a going concern for one year following the issuance of our consolidated financial statements for the quarter ended March 31, 2022. To finance our operations beyond this point, we will need to raise substantial additional capital or effectively implement cost reductions, neither of which can be assured. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders could be further diluted and such dilution may be significant. If we are not able to secure adequate additional funding in future periods, we may make reductions in certain expenditures, which may include suspending or curtailing planned activities and delaying, or reducing the scope of, suspending or eliminating one or more research and development programs or commercialization efforts. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern and that contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Funding Requirements

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, manufacturing development costs, legal and other regulatory expenses, ~~commercialization-related expenses~~ and general administrative costs.

Table of Contents

The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the clinical development of our product candidates and obtain regulatory approvals. We are also unable to predict when, if ever, net cash inflows will commence from product sales. This is due to the numerous risks and uncertainties associated with developing drugs, including, among others, the uncertainty of:

●

the unpredictable duration and economic impact of the COVID-19 pandemic;

●

successful enrollment in, and completion of clinical trials;

● performing preclinical studies and clinical trials in compliance with requirements of the FDA, the European Medicines Agency, or EMA, or any comparable regulatory authority ~~requirements~~;

●

the ability of collaborators to manufacture sufficient quantity of product for development, clinical trials or potential commercialization;

Table of Contents

●

obtaining marketing approvals with labeling for sufficiently broad patient populations and indications, without unduly restrictive distribution limitations or safety warnings, such as black box warnings or a risk evaluation and mitigation strategies program;

●

obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates;

●

making arrangements with third parties for manufacturing capabilities;

●

launching commercial sales of products, if and when approved, whether alone or in collaboration with others;

●

acceptance of the therapies, if and when approved, by physicians, patients and third-party payors;

●

competing effectively with other therapies;

●

obtaining and maintaining healthcare coverage and adequate reimbursement;

●

protecting our rights in our intellectual property portfolio; and

●

maintaining a continued acceptable safety profile of our drugs following approval.

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.

We will not generate revenue from product sales unless and until we or a collaborator successfully complete clinical development and obtain regulatory approval for our current and future product candidates. If we obtain regulatory approval for any of our product candidates that we ~~intend~~ultimately decide to commercialize on our own, we will incur significant expenses related to commercialization, including developing our internal commercialization capability to support product sales, marketing and distribution.

As a result, we will need substantial additional funding to support our continuing operations and to pursue our growth strategy. Until such time, if ever, when we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Table of Contents

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our failure to raise capital as and when needed would compromise our ability to pursue our business strategy.

We will also continue to incur costs as a public company that we did not incur or incurred at lower rates prior to our initial public offering, including increased fees payable to the nonemployee members of our board of directors, increased personnel costs, increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public-company reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq.

Table of Contents

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

~~At-the-Market~~Innoviva, ~~Facility~~Inc. Securities Purchase Agreements

InOn ~~August~~February ~~2021~~1, we2022, ~~entered~~our ~~into~~Board of Directors received a ~~Controlled~~preliminary, ~~Equity~~non-binding ~~Offering~~proposal ~~Sales~~from ~~Agreement,~~Innoviva orto ~~Sales~~acquire ~~Agreement,~~all ~~with~~the ~~Cantor~~outstanding ~~Fitzgerald~~equity &securities ~~Co,~~of orthe ~~Cantor,~~Company that are not currently owned by Innoviva for ~~the~~a ~~offer~~per ~~and~~share ~~sale~~consideration of up$1.80 topayable ~~$17~~in cash.5 ~~million~~On ofMarch 15, 2022, Innoviva revised its ~~common~~non-binding ~~stock~~offer atto acquire the ~~then~~Company ~~current~~to ~~market~~increase ~~prices~~the inper ~~amounts~~share consideration to be$2.00. ~~determined~~All ~~from~~other ~~time~~terms of the offer remain unchanged. The offer letters delivered by Innoviva to ~~time~~our Board of Directors are publicly available in the Schedule 13D amendments dated February 1, 2022 and March 15, 2022, filed by Innoviva with the SEC. ~~There~~Our ~~have~~Board ~~been~~of noDirectors, ~~sales~~which ~~under~~does ~~this~~not ~~program~~include ~~through~~any ~~September~~members 30appointed by or affiliated with Innoviva, ~~2021~~has retained MTS Health Partners, L.P. and Covington & Burling LLP to explore alternatives and to assist the board of directors in its evaluation of the proposal consistent with fiduciary duties.

~~Aspire~~On ~~Common~~February ~~Stock~~17, 2022, we entered into a securities purchase agreement, or the Fourth Securities Purchase Agreement, with a subsidiary of Innoviva, pursuant to which we issued and sold to Innoviva, in a private placement which closed on February 18, 2022, a convertible promissory note having a principal amount of $15.0 million, or the Convertible Note. The Convertible Note is convertible at maturity at the election of us or Innoviva into shares of our common stock at a conversion price of $1.48 per share of common stock and warrants to purchase an equal number of shares of common stock with an exercise price of $1.48 per share of common stock, or the Warrants. As of March 31, 2022, the Convertible Note was convertible into 10,141,852 shares of common stock and 10,141,852 Warrants. The Convertible Note will also be convertible at the option of Innoviva if we engage in certain capital markets transactions, asset sales or royalty transactions. If we are acquired prior to the maturity date of the Convertible Note, the Convertible Note will be payable in cash at the time of such acquisition. The Convertible Note will mature on August 18, 2022 and bears interest at a rate of 0.59% per annum to, but excluding, the date of repayment or conversion of the Convertible Note. From and including the date of maturity, if not converted, the Convertible Note will bear interest at a rate of 10.00% per annum to, but excluding, the date of repayment or conversion of the Convertible Note.

In October 2019, we entered into a common stock purchase agreement, or CSPA, with Aspire Capital Fund, LLC, or Aspire, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $20.0 million of shares of the Company’s common stock over the 30-month term of the CSPA. In advance of our entry into the Sales Agreement with Cantor, we agreed with Aspire to terminate the CSPA. The CSPA was terminated without liability of either party to the other.

Innoviva, Inc. Securities Purchase Agreement

On May 3, 2021, we entered into a securities purchase agreement, or the Third Securities Purchase Agreement, with a subsidiary Innoviva, pursuant to which we agreed to issue and sell to Innoviva, in a private placement up to 10,000,000 newly issued shares of our common stock at $2.00 per share and warrants to purchase up to 10,000,000 shares of common stock, each with an exercise price per share of $2.00, collectively the Third Private Placement. The warrants will be exercisable immediately and will have a five-year term.

As a result of the closings of the three private placements, Innoviva owns approximately 60.6% of our outstanding common stock, without giving effect to the potential exercise of warrants.

Registration Rights Agreements

At the First Closing, we entered into a registration rights agreement with a subsidiary of Innoviva, or the Registration Rights Agreement, pursuant to which, among other things, we must prepare and file with the SEC a registration statement with respect to resales of the shares of common stock and warrants purchased by Innoviva under the Third Securities Purchase Agreement within 90 days of the First Closing. We filed such registration statement on August 2, 2021.

Table of Contents

The Convertible Note and the Warrants will have provisions that preclude conversion or exercise, respectively, if such conversion or exercise would result in the issuance of more than 19.99% of our currently outstanding common stock in the aggregate prior to obtaining stockholder approval.

Registration Rights Agreement

On February 18, 2022, we and Innoviva entered into a registration rights agreement, or the Registration Rights Agreement, pursuant to which, among other things, we must prepare and file with the Securities and Exchange Commission, or the SEC, a registration statement with respect to the resale of shares of common stock and the warrants issuable upon conversion of the Convertible Note and shares of common stock issuable upon exercise of the Warrants within 90 days of the Fourth Securities Purchase Agreement.

Table of Contents

Cash Flows

The following table summarizes our cash flows for the periods presented (in thousands):


	~~Nine~~Three Months Ended
	~~September~~March 3031,
	~~2021~~2022		~~2020~~2021
Net cash used in operating activities	$	(3013,~~683~~751)	$	(3710,~~711~~099)
Net cash (used in) provided by investing activities		(70)		25,000
Net cash used in investing activities		(9)		(11)
Net cash provided by financing activities		2115,~~630~~000		571,~~867~~800
Net (decrease) increase in cash and cash equivalents	$	(9,123)	$	45,156
Net increase (decrease) in cash and cash equivalents	$	1,240	$	(8,310)

Operating Activities

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, operating activities used $3013.7 8 million of cash, resulting from our net loss of $3515.1 3 million, offset by net cash provided by changes in operating assets and liabilities of $10.78 million, and non-cash charges of $20.7 million. Net cash provided by changes in operating assets and liabilities for the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 consisted ~~primarily of~~ a $21.03 million decrease in prepaid expenses, a $0.76 million increase in ~~other~~accounts ~~assets~~payable, ~~and~~ a $0.51 million increase in ~~accounts~~other ~~payable,~~assets ~~partially~~and ~~offset by~~ a $10.1 million ~~increase~~decrease in grants receivable. ~~and~~These were partially offset by a $01.42 ~~increase~~million decrease in accrued expenses and other liabilities.

During the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, operating activities used $3710.71 million of cash, resulting from our net loss of $3910.87 million and net cash used by changes in operating assets and liabilities of $0.23 million, offset by ~~noncash~~non-cash charges of $20.39 million. Net cash used by changes in operating assets and liabilities for the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021 consisted primarily of a $0.7 million ~~decrease~~increase in ~~accounts~~grants ~~payable~~receivable, a $0.75 million decrease in accrued expenses and other liabilities, a $0.4 million increase in other assets and a $0.32 million ~~increase~~decrease in ~~grants~~accounts ~~receivable~~payable. These ~~uses~~ were partially offset by a $1.04 million decrease in prepaid expenses ~~and a $0~~.~~5 million decrease in other assets.~~

Investing Activities

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, net cash used in investing activities was $709,000, consisting of purchases of property, plant, and equipment.

During the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, net cash ~~provided~~used byin investing activities was $~~25.0 million~~11,000, consisting of ~~net~~purchases ~~proceeds~~of ~~from~~property, ~~maturities~~plant, ofand ~~short-term investments~~equipment.

Financing Activities

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, net cash provided by financing activities was $2115.60 million, which consisted of ~~$20.0 million of~~ proceeds from the issuance of ~~common~~our ~~stock~~convertible ~~and warrants in the Third Private Placement, net of financing costs, and $1~~note.~~8 million of proceeds from the exercise of warrants, offset by payments of financing costs of $0.1 million.~~

During the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, net cash provided by financing activities was $571.98 million, which consisted of proceeds from the ~~First~~exercise ~~Private Placement and the Second Private Placement, net~~ of ~~financing costs~~warrants.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Table of Contents

Critical Accounting Policies, Recent Accounting Pronouncements and Significant Judgments and Estimates

There have been no significant changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” disclosed in our most recent Annual Report on Form 10-K.

Refer to Note 2, Summary of Significant Accounting Policies, in the accompanying notes to our unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.

Table of Contents

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure for this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and ~~Chief~~Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of ~~September~~March 3031, ~~2021~~2022. Based upon the evaluation, our Chief Executive Officer and ~~Chief~~Principal Financial and Accounting Officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.

Changes in Internal Control over Financial Reporting.

There were no changes in our internal control over financial reporting that occurred during the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3533

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors.

There have been no material changes in risk factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report filed on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

3634

Table of Contents

Item 6. Exhibits.

ExhibitNumber		Description
3.1		Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38670), filed with the SEC on September 28, 2018).
3.1.1		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38670), filed with the SEC on June 11, 2020).
3.2		Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-38670), filed with the SEC on September 28, 2018).
4.1		Form of Warrant Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-38670), filed with the SEC on May 3, 2021).
31.1		Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of ~~Chief~~Principal Financial and Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certifications of Chief Executive Officer and ~~Chief~~Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 formatted in inline XBRL (included in Exhibit 101).

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

3735

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ENTASIS THERAPEUTICS HOLDINGS INC.

Date: November 4, 2021	By:	/s/ Manoussos Perros, Ph.D.
Date: April 27, 2022	By:	/s/ Manoussos Perros, Ph.D.
		Manoussos Perros, Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: November 4, 2021	By:	/s/ Michael Gutch, Ph.D.
Date: April 27, 2022	By:	/s/ Kristie Wagner
		~~Michael~~Kristie ~~Gutch, Ph.D.~~Wagner
		~~Chief~~Vice ~~Financial~~President, ~~Officer~~Corporate ~~and Chief Business Officer~~Controller
		(Principal Financial ~~Officer~~ and ~~Principal~~ Accounting Officer)

3836

Filing Compare · Entasis Therapeutics Holdings Inc.